{"study_id": 27701, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether myricetin alleviates symptoms of type 2 diabetes and regulates intestinal flora in a mouse model.", "results_summary": "Myricetin significantly reduced fasting blood glucose and blood lipid levels, increased SOD levels, and improved symptoms like polydipsia and weight loss in diabetic mice. It also normalized disrupted intestinal flora in the mice.", "population_specificity": "Type 2 diabetes mouse model induced by high-fat, high-sugar diet and streptozotocin injections.", "effective_dosage": "Not specified", "study_duration": "6 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:04.241720+00:00"}
{"study_id": 27702, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess Myricetin's ability to mitigate acrylamide-induced cytotoxicity and intestinal barrier dysfunction in rat intestinal epithelial cells, and whether heat treatment affected its activity.", "results_summary": "Myricetin reduced acrylamide-induced cell injury by improving viability, decreasing oxidative stress, and restoring intestinal barrier function via tight junction protein expression and JNK/Src pathway suppression, though it was less potent than quercetin. Heat treatment reduced its efficacy.", "population_specificity": "Rat intestinal epithelial (IEC-6) cells", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:04.394811+00:00"}
{"study_id": 27700, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether myricetin could inhibit pyroptosis in lung cancer cells and explore its potential as an antitumor drug by investigating its effects on Gasdermin family proteins and ER stress pathways.", "results_summary": "Myricetin inhibited pyroptosis in lung cancer cells by cleaving GSDME, mediated by caspase-3 activation, and induced ER stress and increased ROS levels. In vivo experiments showed reduced tumor volume and elevated pyroptosis-related protein levels.", "population_specificity": "Lung cancer cells (in vitro and in vivo models)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:04.617244+00:00"}
{"study_id": 27703, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to review Myricetin's role in regulating cellular pathways, its potential in cancer prevention, and its nano-formulations for cancer treatment.", "results_summary": "The study highlights Myricetin's anti-cancer, anti-oxidant, and anti-inflammatory properties, its impact on dysregulated signaling cascades in cancer, but notes limited data on nano-delivery platforms.", "population_specificity": "Not specified (review of preclinical, clinical, and molecular studies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:08.319276+00:00"}
{"study_id": 27704, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether Myricetin loaded in solid lipid nanoparticles (MCN-SLNs) could enhance its anti-cancer effects on HT-29 human colorectal cancer cells compared to free Myricetin.", "results_summary": "MCN-SLNs significantly reduced colony formation and cell viability, increased apoptosis, elevated Bax and AIF expression, decreased Bcl-2 expression, enhanced ROS formation, and reduced mitochondrial membrane potential in HT-29 cells compared to free MCN.", "population_specificity": "HT-29 human colorectal cancer cells", "effective_dosage": "30 \u00b5mol MCN or MCN-SLNs", "study_duration": "24 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:09.759376+00:00"}
{"study_id": 27705, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the hepatoprotective potential of Myricetin in a mouse model of acute liver injury induced by LPS/D-GalN.", "results_summary": "Myricetin (100 mg/kg) reduced mortality, liver damage, and markers of oxidative stress, inflammation, and apoptosis while enhancing antioxidants and modulating autophagy-related factors. The benefits were partially reversed by an autophagy inhibitor.", "population_specificity": "C57BL/6 mice with LPS/D-GalN-induced acute liver injury.", "effective_dosage": "25 or 100 mg/kg/day, orally administered.", "study_duration": "Two days before injury induction.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:11.017511+00:00"}
{"study_id": 27706, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of myricetin on hepatocellular carcinoma (HCC) cells and explore the underlying molecular mechanisms, including ER stress and autophagy.", "results_summary": "Myricetin significantly inhibited HCC cell proliferation and induced apoptosis via ER stress activation, while autophagy was upregulated as a protective response. Combining myricetin with autophagy inhibitors enhanced its anti-HCC effects in vitro and in vivo.", "population_specificity": "Hepatocellular carcinoma (HCC) cells and an HCC xenograft model.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:11.855722+00:00"}
{"study_id": 27710, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to explore the CYP2C8 inhibitory potential of myricetin and its implications for drug interactions using in silico, in vitro, and in vivo methods.", "results_summary": "Myricetin showed substantial CYP2C8 inhibition in human liver microsomes and was identified as a mixed-type inhibitor. It also increased oral exposure of amodiaquine in rats, suggesting potential drug interactions at the hepatic level.", "population_specificity": "Human liver microsomes (in vitro) and rat model (in vivo).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Potential drug interactions via CYP2C8 inhibition, specifically with amodiaquine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:12.879729+00:00"}
{"study_id": 27707, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the therapeutic effects of Myricetin on atopic dermatitis (AD) in mice and its anti-inflammatory mechanisms in human keratinocytes.", "results_summary": "Myricetin alleviated AD symptoms by reducing ear swelling, IgE levels, mast cell infiltration, and inflammatory markers (TARC, IL-4, IFN-\u03b3, TSLP) while increasing filaggrin expression. It also inhibited NF-\u03baB and STAT1 pathways in HaCaT cells.", "population_specificity": "MC903-induced AD mouse model and TNF-\u03b1/IFN-\u03b3-stimulated human immortal keratinocyte line (HaCaT).", "effective_dosage": "Not specified (applied as a cream).", "study_duration": "8 days (in mice).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:13.635101+00:00"}
{"study_id": 27712, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the antioxidant effects of Myricetin (MY) and its impact on in vitro maturation and embryonic development of porcine oocytes.", "results_summary": "Myricetin demonstrated strong antioxidant activity, significantly reducing reactive oxygen species and increasing glutathione levels. It improved polar body extrusion rates and enhanced embryonic development under normal and peroxidative conditions.", "population_specificity": "Porcine oocytes (in vitro study)", "effective_dosage": "10 \u03bcM", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:15.616527+00:00"}
{"study_id": 27713, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the anticancer effects of Myricetin on SK\u2011BR\u20113 human breast cancer cells, focusing on apoptosis and autophagy mechanisms.", "results_summary": "Myricetin reduced cell viability, increased apoptosis, and induced autophagy in SK\u2011BR\u20113 cells via the MAPK pathway, with JNK-mediated regulation playing a key role. Combined treatment with 3-MA enhanced apoptosis, while a JNK inhibitor altered protein expression related to cell viability and autophagy.", "population_specificity": "SK\u2011BR\u20113 human breast cancer cells (in vitro study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:18.185354+00:00"}
{"study_id": 27714, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the glucose-lowering effects of myricetin in type-1 diabetic rats and explore its potential mechanisms involving adropin and \u03b2-endorphin.", "results_summary": "Myricetin dose-dependently increased plasma \u03b2-endorphin and adropin levels, reducing hyperglycemia in diabetic rats. These effects were mediated by GLP-1 receptor activation and were inhibited by its antagonist. Chronic treatment also enhanced adropin secretion.", "population_specificity": "Type-1 diabetic rats and HepG2 cell line.", "effective_dosage": "Not specified (dose-dependent effects noted).", "study_duration": "Acute (bolus injection) and chronic treatment (duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:19.639284+00:00"}
{"study_id": 27715, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of myricetin in preventing ethanol-induced liver toxicity in Wistar rats.", "results_summary": "Myricetin prevented hepatotoxicity by modulating free radicals, ethanol-metabolizing enzymes, and inflammatory markers. It also maintained lipid membrane integrity, oxidant-antioxidant status, and histoarchitecture while reducing elevated hepatotoxicity and cytotoxicity markers.", "population_specificity": "Wistar rats", "effective_dosage": "25 mg/kg and 50 mg/kg body weight, orally", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:19.839694+00:00"}
{"study_id": 27036, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 85, "quality_score": 60, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could effectively treat nonsuicidal self-injurious behavior (NSSIB) in adults with Williams syndrome (WS).", "results_summary": "NAC successfully treated NSSIB in three adults with WS, improving daily functioning, and was well tolerated at doses of 2400 to 3600 mg per day.", "population_specificity": "Adults with Williams syndrome (WS) exhibiting nonsuicidal self-injurious behavior (NSSIB).", "effective_dosage": "2400 to 3600 mg per day", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:21.126669+00:00"}
{"study_id": 27708, "supplement_id": 1363, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if myricetin could inhibit KDM4 members and evaluate its effects on castration-resistant prostate cancer (CRPC), including its potential synergy with enzalutamide.", "results_summary": "Myricetin was identified as a potent inhibitor of KDM4s, reducing proliferation in both androgen-dependent and CRPC cells. Combined with enzalutamide, it showed synergistic cytotoxicity and greater antitumor activity in vivo.", "population_specificity": "Prostate cancer cells (LNCaP, CWR22Rv1, C4-2B) and C4-2B xenograft models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Synergistic effect with enzalutamide noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:22.943106+00:00"}
{"study_id": 27037, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness of high-dose statin alone versus statin plus N-Acetylcysteine (NAC) in preventing contrast-induced nephropathy in patients undergoing PCI.", "results_summary": "The study found that the combination of atorvastatin and NAC significantly reduced serum creatinine and urea levels compared to atorvastatin alone, with contrast-induced nephropathy occurring in 4% of the NAC group versus 18% in the statin-only group (p = 0.025).", "population_specificity": "Patients undergoing elective percutaneous coronary intervention (PCI) at Alshifa Hospital in Gaza (100 patients: 71 male, 29 female; mean age 59 \u00b19.8 years).", "effective_dosage": "NAC 1200 mg orally twice daily every 12 hours for 2 days.", "study_duration": "2 days (NAC intervention).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:24.385781+00:00"}
{"study_id": 27039, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the potential impact of N-Acetylcysteine (NAC) alone on liver disease in individuals with type 1 diabetes mellitus (T1DM) using a beagle model.", "results_summary": "The study found that NAC treatment induced specific activation of CXCL12 chemokine in the liver affected by T1DM, suggesting CXCL12 may play a regulatory role in NAC's therapeutic effects on liver disease associated with T1DM.", "population_specificity": "Beagle model simulating T1DM", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:26.186205+00:00"}
{"study_id": 27041, "supplement_id": 1364, "safety_score": "40", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to determine the role of the Nrf2-HO-1 pathway in the impairment of negative feedback of the HPA axis induced by N-acetylcysteine (NAC).", "results_summary": "NAC reduced Nrf2 expression in the pituitary, induced adrenal enlargement, hypercorticoidism, and altered GR\u03b1/GR\u03b2 expression. CoPPIX treatment reversed these effects, restoring HPA axis feedback.", "population_specificity": "Male Swiss-Webster mice", "effective_dosage": "Not specified", "study_duration": "5 consecutive days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:27.306247+00:00"}
{"study_id": 27040, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to assess the feasibility of conducting a randomized controlled trial (RCT) of N-Acetylcysteine (NAC) for loss of control eating in humans, focusing on recruitment, retention, and adherence.", "results_summary": "The study is a pilot feasibility trial, so efficacy results are not yet available; it will assess changes in eating behaviors and compare ecological momentary assessment (EMA) with retrospective questionnaires.", "population_specificity": "Adult volunteers with loss of control eating.", "effective_dosage": "1200 mg orally twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:27.843815+00:00"}
{"study_id": 27042, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the antibacterial efficacy of N-Acetylcysteine (NAC) against Enterococcus faecalis biofilm as a potential intracanal medicament.", "results_summary": "NAC demonstrated high antimicrobial properties against E. faecalis, showing the second-lowest CFUs at 24 hours and maintaining strong efficacy at 7 days, closely following Aegle marmelos. The study concluded that NAC is a promising novel intracanal medicament.", "population_specificity": "Dentin disc specimens inoculated with E. faecalis biofilm.", "effective_dosage": "Not specified", "study_duration": "24 hours and 7 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:29.428536+00:00"}
{"study_id": 27043, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could remodel the tumor microenvironment in primary and recurrent mouse brain tumors by reducing oxidative stress and improving immune response.", "results_summary": "NAC treatment reduced ROS levels, increased M1-like macrophages and CD8+ T cell infiltration, normalized tumor vasculature, and inhibited tumor growth and recurrence in mouse models.", "population_specificity": "Mouse models of primary (GL261-Luc, CT2A-Luc) and recurrent (GL261-iCasp9-Luc) glioblastoma.", "effective_dosage": "100 mg/kg daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:31.125440+00:00"}
{"study_id": 27047, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness, adverse events, and hospital stay durations between the traditional NAC regimen and the SNAP protocol for treating paracetamol poisoning.", "results_summary": "The SNAP protocol resulted in fewer adverse effects and shorter stays in the ED and hospital compared to the traditional regimen, while both protocols were similarly effective in treating paracetamol poisoning.", "population_specificity": "Patients with paracetamol poisoning requiring NAC treatment in participating hospital EDs (mean age 28.1 years, 70.5% female).", "effective_dosage": "300 mg/kg total dose, administered as 2 intravenous injections (SNAP) or 3 fractions (traditional regimen).", "study_duration": "12 hours (SNAP) vs. 21 hours (traditional regimen).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:35.352099+00:00"}
{"study_id": 27046, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the long-term effects of N-Acetylcysteine (NAC) on reducing major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM).", "results_summary": "NAC users showed a significantly lower incidence of MACE compared to non-users (41.74% vs. 46.87%), with a dose-dependent protective effect\u2014higher cumulative doses correlated with greater risk reduction (aHR: 0.61 for the highest quartile).", "population_specificity": "46,718 T2DM patients from Taiwan's National Health Insurance Research Database (NHIRD), diagnosed between 2008-2018.", "effective_dosage": "Cumulative defined daily doses (cDDD) were used, with the highest quartile (Q4) showing the most significant effect.", "study_duration": "Follow-up until December 31, 2021 (intervention duration not explicitly stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:35.541409+00:00"}
{"study_id": 27049, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to assess the antimicrobial efficacy of N-acetylcysteine (NAC) as an endodontic irrigant or intracanal medication compared to sodium hypochlorite, chlorhexidine, and calcium hydroxide against endodontic pathogens.", "results_summary": "NAC effectively reduced Enterococcus faecalis, showing comparable antimicrobial activity to chlorhexidine and sodium hypochlorite, particularly at concentrations of 25-50 mg/mL over a 7-day exposure. Despite significant heterogeneity across studies, NAC demonstrated satisfactory antimicrobial effects in vitro.", "population_specificity": "Teeth requiring endodontic treatment (in vitro studies only).", "effective_dosage": "25-50 mg/mL", "study_duration": "7-day exposure", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:36.327955+00:00"}
{"study_id": 27050, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 40, "study_goal": "The researchers aimed to investigate the potential benefits of N-Acetylcysteine (NAC) in treating acute hepatitis caused by cocaine intoxication.", "results_summary": "The study found that NAC administration, alongside dialysis and supportive measures, led to improved liver function and decreased transaminases in a patient with cocaine-induced acute hepatitis. The abstract suggests NAC may warrant further investigation for such cases, though it is currently only used for acetaminophen-related toxic hepatitis.", "population_specificity": "A 28-year-old woman with acute hepatitis due to cocaine intoxication.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:37.855685+00:00"}
{"study_id": 27051, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could slow disease progression in retinitis pigmentosa (RP) patients by reducing oxidative stress and providing neuroprotective effects.", "results_summary": "Initial clinical studies showed improvements in visual acuity and macular function with NAC therapy, though no structural changes were observed. The ongoing Phase III trial \"NAC Attack\" seeks to evaluate long-term efficacy and safety.", "population_specificity": "Patients with retinitis pigmentosa (RP).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:38.760442+00:00"}
{"study_id": 27053, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the effectiveness of a novel chitosan-N-acetylcysteine (CS-NAC) conjugate in enhancing the delivery and therapeutic effects of dexamethasone for treating dry eye syndrome.", "results_summary": "The study found that CS-NAC@Dex-NLC improved drug bioavailability, enhanced corneal penetration and retention, and effectively alleviated dry eye symptoms while reducing inflammation. The system demonstrated excellent biocompatibility and safety.", "population_specificity": "Rabbits with dry eye syndrome.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:43.719587+00:00"}
{"study_id": 27055, "supplement_id": 1364, "safety_score": "90", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of N-acetylcysteine (NAC) infusion in treating acute aluminum phosphide poisoning.", "results_summary": "NAC reduced oxidative stress markers (lower MDA, higher TAC) and improved blood pressure and hospitalization duration, but did not significantly affect mortality or mechanical ventilation needs. No adverse effects were reported.", "population_specificity": "96 patients with acute aluminum phosphide poisoning.", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:44.139704+00:00"}
{"study_id": 27052, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of N-Acetylcysteine (NAC) on reproductive outcomes, including follicular growth, endometrial thickness, and hormone levels, in women with PCOS compared to placebo and other treatments.", "results_summary": "NAC significantly increased progesterone levels and endometrial thickness compared to placebo and other drugs, and it also raised LH levels compared to metformin. No significant differences were observed in estradiol, SHBG, or FSH levels.", "population_specificity": "Women with polycystic ovary syndrome (PCOS) of reproductive age.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:44.238552+00:00"}
{"study_id": 27054, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could enhance recovery from VX poisoning by reducing cholinergic and oxidative stress-mediated toxicity when used alongside standard atropine-oxime treatment.", "results_summary": "NAC administration alongside standard therapy increased brain cholinesterase activity recovery from 51% to 89%, maintained GSH levels, reduced ROS generation and lipid peroxidation, and prevented VX-induced cellular damage.", "population_specificity": "Animal model (specific species not mentioned) exposed to VX poisoning.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:44.390380+00:00"}
{"study_id": 27038, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could protect against 5-FU-induced cardiac injury while preserving its anticancer efficacy and to explore the underlying mechanisms.", "results_summary": "NAC significantly reduced cardiac enzyme levels, improved heart tissue histology, enhanced antioxidant activity, decreased inflammation, and reduced apoptosis markers compared to 5-FU alone, demonstrating cardioprotective effects.", "population_specificity": "Rats (n = 8 per group)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:44.464481+00:00"}
{"study_id": 27048, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could mitigate oxidative damage and apoptosis in the heart tissue of male rats treated with nandrolone (ND), focusing on the TLR4/NF-\u03baB/NLRP3 signaling pathway.", "results_summary": "NAC treatment reduced the negative effects of ND, including DNA damage, apoptosis, and oxidative stress markers, suggesting its role as an antioxidant and anti-inflammatory agent in protecting heart tissue.", "population_specificity": "Male Wistar rats (weight range 220 \u00b1 10 g)", "effective_dosage": "Not specified", "study_duration": "6 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:47.412918+00:00"}
{"study_id": 27057, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of N-Acetylcysteine (NAC) perfusion on 5-year overall survival and graft survival in liver transplant recipients, particularly in marginal liver donors.", "results_summary": "The study found that NAC perfusion significantly improved 5-year overall survival (84% vs. 63%) and graft survival compared to the control group, with notable benefits in HCC and HCV transplant indications. Cost analysis also indicated negligible resource requirements for the NAC protocol.", "population_specificity": "Liver transplant recipients, with a focus on marginal liver donors and specific subgroups like HCC and HCV patients.", "effective_dosage": "Not specified", "study_duration": "5-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:47.971232+00:00"}
{"study_id": 27059, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of adjunctive N-Acetylcysteine (NAC) on biomarkers of oxidation, inflammation, and infection in patients with pulmonary tuberculosis.", "results_summary": "NAC increased total glutathione, reduced MTB-induced TNF-\u03b1, and accelerated hemoglobin recovery but slowed MTB clearance from sputum. It showed antioxidant and anti-inflammatory effects but no enhanced antimicrobial activity.", "population_specificity": "140 adults with moderate or far-advanced pulmonary tuberculosis.", "effective_dosage": "1200 mg twice daily.", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:52.427837+00:00"}
{"study_id": 27060, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the impact of N-acetylcysteine (NAC) on testicular hypoxia caused by varicocele, focusing on its effects on apoptosis and oxidative stress-related genes in rats.", "results_summary": "NAC administration improved testicular histopathology, increased antioxidant markers (GPx and SOD), reduced oxidative stress (MDA), decreased Bax expression, enhanced Bcl-2 expression, and reduced germ cell apoptosis in hypoxic rats.", "population_specificity": "Mature Wistar rats with induced testicular hypoxia from varicocele.", "effective_dosage": "Not specified", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:52.455276+00:00"}
{"study_id": 27061, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the anti-microbial role of N-Acetylcysteine (NAC) against Cutibacterium acnes in acne vulgaris patients, focusing on its ability to reduce biofilm formation and improve antibiotic sensitivity.", "results_summary": "NAC, along with isotretinoin and salicylic acid, improved azithromycin and doxycycline sensitivity and reduced the biofilm formation ability of C. acnes, suggesting its potential as an adjuvant in acne treatment.", "population_specificity": "48 acne vulgaris patients aged 16-30 years with varying disease grades.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:53.056408+00:00"}
{"study_id": 27062, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the utility of N-Acetylcysteine (NAC) in managing severe acute renal failure in patients with congenital thrombotic thrombocytopenic purpura (cTTP).", "results_summary": "The study found that daily plasma exchange and NAC were useful in treating severe acute renal failure in cTTP patients, particularly when infections triggered acute hemolytic episodes. Regular use of ADAMTS13-containing products, alongside NAC, helped reverse thrombotic microangiopathy episodes and reduce long-term morbidity and mortality.", "population_specificity": "Patients with congenital thrombotic thrombocytopenic purpura (cTTP) experiencing severe acute renal failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:53.787741+00:00"}
{"study_id": 27058, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine (NAC) as an antioxidant in acute organophosphate (OP) poisoning by comparing its effects with standard treatment.", "results_summary": "NAC significantly elevated serum catalase and glutathione peroxidase levels but did not significantly affect clinical outcomes such as atropine requirements, duration of treatment, need for mechanical ventilation, or hospital stay. Mortality was lower in the NAC group, but the difference was not statistically significant.", "population_specificity": "56 acute OP-poisoned patients admitted to the ICU within 6 hours of exposure.", "effective_dosage": "300 mg/kg administered intravenously.", "study_duration": "Not specified (study period was January to June 2022).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:54.230857+00:00"}
{"study_id": 27064, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether delayed administration of N-Acetylcysteine (NAC) could prevent cisplatin-induced cognitive impairments in an ovarian cancer xenograft rat model without compromising cisplatin's anti-cancer efficacy.", "results_summary": "Delayed NAC administration prevented cognitive impairments in tumor-bearing rats without affecting cisplatin-induced tumor volume reduction. In vitro, NAC mitigated hippocampal dendritic branching damage and neuronal apoptosis without decreasing cisplatin's anti-cancer efficacy.", "population_specificity": "Female Cr:NIH-RNU rats with ovarian cancer xenografts (SKOV3.ip1 cells).", "effective_dosage": "250 mg/kg/day, administered for five consecutive days during cisplatin treatment.", "study_duration": "Five days per cisplatin cycle, over four cycles (total of 20 days).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:57.865137+00:00"}
{"study_id": 27063, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to explore the diagnostic process, management strategies, and therapeutic role of N-acetylcysteine (NAC) in treating drug-induced liver injury (DILI).", "results_summary": "The study highlights NAC's mechanism of action, current clinical applications, and potential future uses in DILI management, suggesting its therapeutic value in such cases.", "population_specificity": "A 65-year-old male patient suspected of DILI following tuberculosis treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:49:58.571219+00:00"}
{"study_id": 27065, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could mitigate cognitive and neuromuscular deficits induced by cisplatin (CIS) by modulating brain kynurenic acid (KYNA) levels and improving redox imbalance.", "results_summary": "NAC co-administration prevented CIS-induced long-term memory deficits, muscle weakness, and redox imbalance while attenuating increased KYNA levels and KATII activity. NAC improved the GSH/GSSG ratio and reduced lipid peroxidation in brain tissue.", "population_specificity": "Female Wistar rats treated with cisplatin.", "effective_dosage": "300 mg/day for 8 days.", "study_duration": "8 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:01.402289+00:00"}
{"study_id": 27070, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine (NAC) as an adjuvant therapy for rheumatoid arthritis (RA) by assessing its impact on disease activity and inflammatory markers.", "results_summary": "NAC was found to alleviate disease activity in RA patients, reducing inflammatory markers and improving joint tenderness and swelling, but did not show significant effects on oxidative stress.", "population_specificity": "204 patients with rheumatoid arthritis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:01.896547+00:00"}
{"study_id": 27069, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether combined N-acetylcysteine (NAC) and low-dose estrogen treatment could protect against cardiometabolic dysfunction and cardiac ischemia-reperfusion injury in estrogen-deprived obese rats.", "results_summary": "Combined NAC and low-dose estrogen treatment showed similar efficacy to regular-dose estrogen in improving heart rate variability, left ventricular function, and reducing cardiac mitochondrial dysfunction and infarct size during ischemia-reperfusion injury.", "population_specificity": "Female estrogen-deprived obese Wistar rats with cardiac ischemia-reperfusion injury.", "effective_dosage": "100 mg/kg/d NAC, 25 \u03bcg/kg/d low-dose estrogen.", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:02.934221+00:00"}
{"study_id": 27066, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of different NAC concentrations on semen quality during cryopreservation in Qianbei Ma goats.", "results_summary": "NAC-treated groups showed improved post-thaw sperm motility, higher antioxidant enzyme activity, lower ROS levels, and better cell structure compared to the control. The 9 mM NAC treatment demonstrated the most significant benefits.", "population_specificity": "Semen samples from five Qianbei Ma goats with motility rates above 80%.", "effective_dosage": "3 mM and 9 mM NAC in semen extenders.", "study_duration": "Not specified (cryopreservation and thawing process).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:03.890925+00:00"}
{"study_id": 27067, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-acetylcysteine could reduce lipid accumulation and modulate lipid metabolism in HepG2 cells induced to mimic non-alcoholic fatty liver disease.", "results_summary": "N-acetylcysteine increased fatty acid \u03b2-oxidation gene expression, decreased lipogenesis-related gene expression, reduced lipid droplets in a dose-dependent manner, and modulated apoptotic gene expression (lower BAX, higher BCL2).", "population_specificity": "HepG2 cells (a human liver cell line) induced to mimic non-alcoholic fatty liver disease.", "effective_dosage": "Varying concentrations, with 10mM showing significant effects.", "study_duration": "48 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:04.310599+00:00"}
{"study_id": 27072, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the mechanisms and inflammatory pathways through which NAC may manage neuropathic and musculoskeletal pain.", "results_summary": "The study found that NAC can attenuate neuropathic and musculoskeletal pain by inhibiting MMPs, reducing ROS, and enhancing glutamate transport. It may also synergize with opioids and other pain medications, potentially reducing opioid consumption.", "population_specificity": "Not specified (general focus on neuropathic and musculoskeletal pain conditions).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "Synergistic effects with opioids and other pain medications mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:06.432063+00:00"}
{"study_id": 27056, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine (NAC) in modifying mucus dysfunction and its potential as an early treatment for individuals at risk of COPD development.", "results_summary": "NAC was found to improve mucus clearance, reduce MUC5AC expression, and exert antioxidant and anti-inflammatory effects, potentially reducing symptoms and improving outcomes in COPD patients. Some clinical experiences support its adjunctive use, though further evidence is needed.", "population_specificity": "Subjects at risk of or with chronic obstructive pulmonary disease (COPD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:06.495331+00:00"}
{"study_id": 27071, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine the effects of N-Acetylcysteine (NAC) on oxidative stress, intracellular Mycobacterium tuberculosis (MTB) load, apoptosis, and autophagy in infected macrophages, and explore its potential mechanism of action for tuberculosis treatment.", "results_summary": "NAC reduced oxidative stress (ROS and MDA levels) and autophagy (LC3II/\u03b2-actin ratio) in MTB-infected macrophages, while initially increasing but later decreasing intracellular MTB colony-forming units (CFUs).", "population_specificity": "THP-1 macrophages infected with H37Rv MTB strain.", "effective_dosage": "Not specified", "study_duration": "Measurements taken at 0, 4, 24, and 48 hours post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:07.962116+00:00"}
{"study_id": 27074, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to investigate the protective mechanism of N-Acetylcysteine (NAC) against smoking-induced airway injuries using human airway organoids.", "results_summary": "The study found that NAC binds to nicotine, preventing its interaction with nicotinic acetylcholine receptors (nAChRs), thereby mitigating nicotine-induced airway injury, contrary to the traditional antioxidative mechanism.", "population_specificity": "Human tissue-derived airway organoids (primarily ciliated, basal, goblet, and myofibroblast-like cells).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:10.395416+00:00"}
{"study_id": 27073, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could mitigate inflammation and oxidative stress in a mouse model of ASD (Shank3b-deficient mice) and improve ASD-related behaviors.", "results_summary": "NAC treatment reduced inflammation in the cerebellum and peripheral blood, suppressed pro-inflammatory molecule production in the bone marrow and spleen, and improved social impairment in Shank3b-/- mice. The findings suggest NAC may counteract systemic inflammation and behavioral deficits in ASD.", "population_specificity": "Shank3b-deficient mice (a model of syndromic autism spectrum disorder).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:11.295336+00:00"}
{"study_id": 27076, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 35, "quality_score": 75, "study_goal": "The researchers aimed to examine the efficacy of N-Acetylcysteine (NAC) in reducing craving symptoms in individuals with substance use disorders (SUDs) and to explore subgroup differences, risk of bias, and publication bias across trials.", "results_summary": "The meta-analysis found that NAC did not significantly outperform placebo in reducing craving symptoms, with high heterogeneity and potential publication bias, suggesting limited impact of NAC on substance craving.", "population_specificity": "Individuals with substance use disorders (SUDs), primarily targeting alcohol, tobacco, and multiple substances.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:12.511338+00:00"}
{"study_id": 27077, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to assess the effect of N-acetylcysteine (NAC) as an adjuvant treatment on treatment adherence, peripheral biomarkers, and clinical improvement in patients with alcohol use disorders (AUD).", "results_summary": "The study found that NAC did not significantly differ from placebo in treatment adherence, clinical improvement, or relapse time. However, NAC showed effects on oxidative stress markers (reduced GSSG levels) and neuropeptide Y (NPY) levels, though these changes did not translate to clinical benefits.", "population_specificity": "53 inpatients with alcohol use disorders (AUD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "9 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:13.732137+00:00"}
{"study_id": 27075, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether high-dose intravenous N-Acetylcysteine (NAC) improves clinical outcomes in mechanically ventilated patients with severe COVID-19 pneumonia.", "results_summary": "The study found no significant improvement in 28-day mortality, ventilator-free days, or ICU/hospital length of stay with high-dose NAC. NAC showed a trend toward quicker reduction in C-reactive protein in patients not treated with tocilizumab, but this was not statistically significant.", "population_specificity": "Mechanically ventilated adults (\u226518 years) with acute respiratory failure (PaO2/FiO2 ratio <300) due to SARS-CoV-2 infection.", "effective_dosage": "10 g per day (high-dose intravenous NAC).", "study_duration": "Not explicitly stated (follow-up period was 28 days).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:14.648530+00:00"}
{"study_id": 27081, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether oral N-Acetylcysteine (NAC) could prevent or reduce taxane-induced neuropathy in breast cancer patients undergoing chemotherapy.", "results_summary": "The study found no significant difference in the incidence or severity of neuropathy between the NAC and placebo groups at 1 and 12 weeks post-chemotherapy, suggesting oral NAC at 1200 mg/day was ineffective for this purpose.", "population_specificity": "80 breast cancer patients undergoing taxane-based chemotherapy.", "effective_dosage": "1200 mg of oral NAC per day, divided doses.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:16.926650+00:00"}
{"study_id": 27080, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 68, "quality_score": 82, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine (NAC) in ameliorating depressive symptoms in patients with psychiatric disorders, particularly bipolar disorder and major depressive disorder.", "results_summary": "The meta-analysis found a statistically significant but modest reduction in depression scores with NAC compared to placebo (standardized mean difference = -0.24). The results suggest NAC may be beneficial as an adjunctive treatment, but the wide confidence interval indicates the need for further large-scale trials.", "population_specificity": "Patients with psychiatric problems, including bipolar disorder and major depressive disorder (904 participants across 12 studies).", "effective_dosage": "1000 to 3000 mg daily.", "study_duration": "8 to 24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:17.000109+00:00"}
{"study_id": 27082, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could mitigate depressive-like and impulsive behaviors induced by early-life stress in rats and EAAC1-deficient mice.", "results_summary": "NAC improved depressive-like behaviors in both male and female rats subjected to early-life stress and reduced oxidative stress and neuroinflammation in the ventral hippocampus and prefrontal cortex. However, NAC only improved impulsive behavior in males and had limited effects in EAAC1-deficient mice.", "population_specificity": "Adolescent rats (male and female) subjected to neonatal maternal separation and social isolation, and EAAC1-deficient mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:19.252391+00:00"}
{"study_id": 27084, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could repair injury in the extrahepatic biliary tree of Mdr2-/- mice and improve liver fibrosis.", "results_summary": "NAC treatment improved duct morphology in ex vivo explants and reduced liver fibrosis and enzyme activities in vivo, indicating a shift from pro-apoptotic to proliferative states.", "population_specificity": "Mdr2-/- mice (a cholestatic mouse model) aged 2 to 40 weeks.", "effective_dosage": "Not specified", "study_duration": "3 weeks (in vivo oral administration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:21.206254+00:00"}
{"study_id": 27085, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine (NAC) could protect against Nano-ITO-induced pulmonary alveolar proteinosis in rats by modulating the NF-\u03baB signaling pathway.", "results_summary": "NAC significantly reduced oxidative stress, inflammation, and NF-\u03baB pathway activation in Nano-ITO-exposed rats, demonstrating protective effects against pulmonary toxicity.", "population_specificity": "Adult male Sprague-Dawley rats", "effective_dosage": "200 mg/kg NAC, administered intraperitoneally 1.5 hours before Nano-ITO exposure", "study_duration": "12 weeks (twice weekly exposure)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:22.198841+00:00"}
{"study_id": 27078, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential benefits of N-Acetylcysteine (NAC) in managing COPD through the treatable trait strategy, focusing on its mucolytic, antioxidant, and anti-inflammatory properties.", "results_summary": "The study found that NAC could improve frequent productive cough, airflow limitations, airway inflammation, exacerbations, and bronchiectasis in COPD patients, contributing to better symptom management and quality of life.", "population_specificity": "Patients with chronic obstructive pulmonary disease (COPD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:23.121436+00:00"}
{"study_id": 27083, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the impact of N-Acetylcysteine (NAC) on mucus hypersecretion (MHS) in airways, particularly its effects on MUC5AC and MUC5B expression and goblet cell hyperplasia, to assess its potential as a targeted therapy for COPD.", "results_summary": "The study found that NAC significantly inhibited MUC5AC and MUC5B gene and protein expression and reduced goblet cell numbers, demonstrating efficacy in vitro and in animal models of MHS, including COPD. However, data on human bronchial tissue were lacking, necessitating further research for clinical translation.", "population_specificity": "In vitro and animal models (including COPD models); human bronchial tissue not assessed.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:23.128620+00:00"}
{"study_id": 27087, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine (NAC), alone and in combination with calcium hydroxide, against Enterococcus faecalis, Escherichia coli, and their lipopolysaccharides in endodontic infections.", "results_summary": "NAC combined with calcium hydroxide significantly reduced E. faecalis, E. coli, and LPS levels after 7 days, outperforming individual treatments for LPS reduction. No significant differences were found among treatments for microbial load reduction alone.", "population_specificity": "Single-rooted human teeth infected with E. faecalis and E. coli.", "effective_dosage": "Not specified", "study_duration": "7 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:27.396072+00:00"}
{"study_id": 27089, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the beneficial effects of N-Acetylcysteine (NAC) in treating liver diseases, focusing on its antioxidant, immunomodulatory, and epigenetic mechanisms.", "results_summary": "NAC demonstrated efficacy in preventing liver damage through antioxidant properties, glutathione precursor activity, and modulation of signaling pathways and epigenetic markers. Its effectiveness and safety were dose-dependent, highlighting the need for optimized pharmacological formulations.", "population_specificity": "Patients with liver diseases (clinical and experimental studies).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:27.465034+00:00"}
{"study_id": 27088, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the therapeutic potential of N-Acetylcysteine (NAC) as a treatment or adjunct therapy for various medical conditions, including chronic diseases.", "results_summary": "NAC demonstrated efficacy in treating acetaminophen overdose, cystic fibrosis, and chronic obstructive pulmonary disease, with emerging evidence supporting its benefits for a broader range of conditions such as neurodegenerative disorders, inflammatory diseases, and mental health conditions. While evidence for some conditions is less robust, NAC's safety, affordability, and potential therapeutic effects warrant further investigation.", "population_specificity": "Broad spectrum of medical conditions (e.g., chronic diseases, neurodegenerative disorders, inflammatory diseases, mental health conditions).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:27.826361+00:00"}
{"study_id": 27090, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the pharmacokinetics, mechanisms of action, and optimal administration strategies of N-Acetylcysteine (NAC) in kidney disease, considering factors like dosage, timing, and patient-specific conditions.", "results_summary": "NAC demonstrated beneficial effects in both acute and chronic kidney disease, with efficacy influenced by dosage, timing of administration, and patient kidney function. High concentrations of NAC may cause reductive stress, and delayed administration could interfere with endogenous repair mechanisms.", "population_specificity": "Patients with acute or chronic kidney disease (CKD).", "effective_dosage": "Not specified (discusses pharmacokinetics but no exact dosage provided).", "study_duration": "Not specified (focuses on timing relative to injury rather than duration).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:30.536416+00:00"}
{"study_id": 27091, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-acetylcysteine could influence the \u0394FosB pathway to reduce relapse risk in substance use disorders.", "results_summary": "The study suggests N-acetylcysteine may modulate the \u0394FosB downstream pathway, potentially offering a low-cost, well-tolerated treatment to mitigate relapse in substance use disorders. However, specific clinical outcomes or effect sizes are not detailed in the abstract.", "population_specificity": "Individuals with substance use disorders (specific substance not specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:30.604251+00:00"}
{"study_id": 27093, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could improve clinical recovery in neonatal calves with pneumonia by reducing clinical scores, shortening treatment duration, and enhancing overall health.", "results_summary": "NAC supplementation significantly reduced recovery time by over 27 hours compared to antimicrobial-only treatment, demonstrating clinically meaningful benefits in neonatal calves with pneumonia.", "population_specificity": "Neonatal calves with respiratory diseases (pneumonia).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:31.851996+00:00"}
{"study_id": 27092, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of N-Acetylcysteine (NAC) on endocrine-metabolic parameters in PCOS mice and its impact on ovulation induction efficacy in women with PCOS.", "results_summary": "NAC improved estrous cycles, ovarian phenotypes, and insulin sensitivity in PCOS mice while reducing oxidative stress. In women with PCOS, NAC enhanced ovulation induction efficacy, reducing required uFSH dosage and increasing pregnancy rates.", "population_specificity": "Female C57BL/6 mice with induced PCOS and 230 women diagnosed with PCOS.", "effective_dosage": "160 mg/kg daily in mice; 1.8 g/day orally in women.", "study_duration": "12 days in mice; \u22643 ovulation induction cycles in women.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:33.510307+00:00"}
{"study_id": 27096, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 30, "quality_score": 90, "study_goal": "The researchers aimed to assess the efficacy of N-Acetylcysteine (NAC) in relieving dryness symptoms in patients with Sj\u00f6gren's disease (SjD).", "results_summary": "The study found no significant differences between NAC and placebo in improving dryness symptoms or reducing oxidative stress, except for a transient decrease in ESSPRI at 30 days. Unstimulated salivary flow was higher in the placebo group at 90 days.", "population_specificity": "60 adult females with Sj\u00f6gren's disease and low disease activity.", "effective_dosage": "1,200 mg/day orally.", "study_duration": "90 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:36.208341+00:00"}
{"study_id": 27094, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "To investigate the intervention effect and mechanism of N-acetylcysteine (NAC) on ultrafine carbon black-induced oxidative damage, autophagy, and apoptosis in human bronchial epithelial cells (BEAS-2B cells).", "results_summary": "NAC significantly reduced oxidative damage, autophagy, and apoptosis in BEAS-2B cells exposed to ultrafine carbon black by lowering ROS and MDA levels, increasing antioxidant enzyme activities, and modulating autophagy and apoptosis-related gene expressions.", "population_specificity": "Human bronchial epithelial cells (BEAS-2B cells) in vitro.", "effective_dosage": "2 mmol/L NAC for 1 hour pretreatment.", "study_duration": "24 hours (following NAC pretreatment).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:36.741741+00:00"}
{"study_id": 27095, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the safety and efficacy of N-Acetylcysteine (NAC) as an augmentation therapy with SSRIs for treating moderate to severe OCD.", "results_summary": "NAC augmentation showed a positive outcome in reducing Y-BOCS scores over 5-8 weeks but no significant effects for shorter or longer durations. No significant differences in adverse events were observed between NAC and control groups.", "population_specificity": "Patients with moderate to severe obsessive-compulsive disorder (OCD).", "effective_dosage": "Not specified", "study_duration": "5-12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:36.933577+00:00"}
{"study_id": 27098, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether high-dose N-acetylcysteine reduces exacerbations and improves lung function in patients with mild-to-moderate COPD.", "results_summary": "The study found no significant difference in the annual rate of total exacerbations or lung function improvement between the N-acetylcysteine and placebo groups after two years of treatment.", "population_specificity": "Patients aged 40-80 with mild-to-moderate COPD (FEV1 \u2265 50% predicted post-bronchodilator).", "effective_dosage": "600 mg, twice daily", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:38.715089+00:00"}
{"study_id": 27097, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of dietary N-Acetylcysteine (NAC) supplementation on muscle and liver health in LPS-challenged weaned piglets.", "results_summary": "NAC reversed LPS-induced increases in IL-1\u03b2, CXCR3, and IFN-\u03b3 in the liver, restored IGF-1, T-GSH, and protein-to-DNA ratios, and mitigated oxidative stress in muscles. It also regulated genes linked to type I interferon signaling, HIF1, and Nrf-2 pathways.", "population_specificity": "24-day-old weaned piglets", "effective_dosage": "500 mg/kg NAC in diet", "study_duration": "21 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:39.245248+00:00"}
{"study_id": 27100, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) has antiviral effects against Coxsackievirus B3 (CVB3) and its potential mechanism of action.", "results_summary": "NAC significantly suppressed CVB3 replication, alleviated cardiac injury, and downregulated the expression of eEF1A1, a protein facilitating viral replication, by promoting autophagy.", "population_specificity": "CVB3-infected cells and mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:41.125848+00:00"}
{"study_id": 27099, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether minocycline plus N-acetylcysteine (MN12) could restore synaptic plasticity and cognitive function in mice with closed-head injury by targeting PKM\u03b6.", "results_summary": "MN12 restored hippocampal PKM\u03b6 levels, synaptic plasticity (E-LTP and L-LTP), and Barnes maze acquisition in injured mice, with effects mediated by PKM\u03b6 activity.", "population_specificity": "Mice with closed-head injury (CHI).", "effective_dosage": "Not specified (only timing\u201412 hours post-CHI\u2014is mentioned).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:41.389266+00:00"}
{"study_id": 27101, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of topically applied NAC-enriched hydrogels on wound healing in a leptin-deficient murine model of type II diabetes.", "results_summary": "Wounds treated with 5% NAC showed improved wound closure speed and increased dermal proliferation compared to other groups, while higher concentrations (10% and 20%) did not demonstrate beneficial effects. The study suggests that 5% NAC may enhance early wound healing in type II diabetes by promoting dermal proliferation.", "population_specificity": "Leptin-deficient (db/db) mice, a model for type II diabetes.", "effective_dosage": "5%, 10%, and 20% NAC in hydrogels (topical application).", "study_duration": "28 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:44.971718+00:00"}
{"study_id": 27086, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether inhibiting oxidative stress with N-Acetylcysteine (NAC) reduces morphine self-administration in an animal model of opioid dependence.", "results_summary": "NAC administration led to a mild reduction in voluntary morphine intake and significantly reduced oxidative stress and neuroinflammation in the hippocampus. Combined with ibudilast, NAC resulted in a marked inhibition (-57%) of morphine self-administration and restored normal levels of the glutamate transporter GLT-1 in the nucleus accumbens.", "population_specificity": "Wistar-derived UChB rats (animal model of opioid dependence).", "effective_dosage": "40 mg/kg/day", "study_duration": "Extended period (exact duration not specified in abstract).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:44.978005+00:00"}
{"study_id": 27103, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether N-Acetylcysteine (NAC) could protect against oxidative damage in female rabbit ovaries induced by D-galactose.", "results_summary": "NAC at 0.1 mg/mL effectively alleviated D-gal-induced oxidative damage, restored antioxidant enzyme levels (GSH, T-SOD, CAT), and counteracted the downregulation of key oxidative stress-related genes (Nrf2, GPX, PRDX4, GSR, SOD1, TAF4B).", "population_specificity": "Female rabbit ovaries (in vitro study).", "effective_dosage": "0.1 mg/mL NAC.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:45.429688+00:00"}
{"study_id": 27102, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether N-acetylcysteine (NAC) could prevent complex regional pain syndrome type 1 (CRPS-1) by reducing proinflammatory cytokines and oxidative stress markers in patients with distal radius fractures.", "results_summary": "NAC significantly reduced the incidence of CRPS-1 (9.7% vs. 31.0% in controls), lowered proinflammatory cytokine levels (IL-6, TNF-\u03b1, IL-1), and improved oxidative stress markers (higher TAS, lower TOS). Logistic regression showed a 78% reduction in CRPS-1 odds with NAC treatment.", "population_specificity": "Patients over 50 years of age with distal radius fractures (mean age 62.8 \u00b1 5.1 years; 26 males, 34 females).", "effective_dosage": "600 mg NAC daily.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:47.392572+00:00"}
{"study_id": 27104, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) reduces craving ratings in patients with substance use disorder (SUD) compared to placebo, while also assessing withdrawal symptoms, side effects, and dropouts.", "results_summary": "NAC reduced craving ratings in SUD patients, though the evidence was weak, with no significant differences in withdrawal symptoms or side effects between NAC and placebo groups. Dropout rates slightly favored placebo but were not statistically significant.", "population_specificity": "Patients with substance use disorder (alcohol, cocaine, poly-drugs, amphetamine, nicotine).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:47.463679+00:00"}
{"study_id": 27105, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) could attenuate the side effects of donepezil and investigate the underlying mechanisms.", "results_summary": "NAC significantly reduced both acute and chronic muscle-related symptoms caused by high-dose donepezil in rats. In vitro studies showed NAC dramatically reduced ROS and intracellular calcium levels in muscle cells, which contributed to these adverse effects.", "population_specificity": "Five-week-old Sprague-Dawley rats and C2C12 myotubes.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Four weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:47.624227+00:00"}
{"study_id": 27107, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-acetylcysteine could prevent THC-induced neurodevelopmental pathology and associated behavioral abnormalities in an adolescent rat model.", "results_summary": "N-acetylcysteine prevented THC-induced neuronal and molecular abnormalities in the nucleus accumbens and reduced anxiety- and depressive-like behaviors in adolescent rats.", "population_specificity": "Adolescent rats exposed to THC.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:48.467213+00:00"}
{"study_id": 27106, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) could mitigate radiation-induced heart damage by reducing oxidative stress and mitochondrial dysfunction.", "results_summary": "NAC treatment reduced oxidative stress, improved antioxidant levels, and restored mitochondrial function in irradiated cardiomyocytes, but did not reverse DNA damage.", "population_specificity": "8-week-old male Sprague-Dawley rats and H9C2 cells.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:48.670495+00:00"}
{"study_id": 27110, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of N-Acetylcysteine (NAC) combined with Ambroxol Hydrochloride (AH) on clinical symptoms, inflammatory markers, lung function, and immune response in children with pneumonia.", "results_summary": "NAC combined with AH showed higher effectiveness, faster symptom relief, reduced inflammatory markers (CRP, PCT), improved lung function, and enhanced immune response compared to AH alone, with no significant difference in adverse reactions.", "population_specificity": "Children with pneumonia (n=98, divided into control and observation groups).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:54.516864+00:00"}
{"study_id": 27109, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of nebulized N-Acetylcysteine (NAC) in improving phlegm symptoms in COPD patients over 12 weeks.", "results_summary": "Nebulized NAC significantly reduced the CAT phlegm score from 3.47 to 2.62 (p < 0.01) after 12 weeks, with 53.5% of patients expressing satisfaction. Adverse events occurred in 8% of patients, but no serious adverse drug reactions were reported.", "population_specificity": "COPD patients aged \u226540 years, current or ex-smokers with \u226510 pack-years, and a baseline CAT phlegm score \u22652.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:55.090406+00:00"}
{"study_id": 27111, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of N-Acetylcysteine (NAC) on serum levels of electrolytes, enzymes, oxidative stress biomarkers, and hangover symptoms in binge drinking.", "results_summary": "NAC had no effect on serum sodium, urea, or 8-OHdG levels and did not alleviate hangover symptoms. Binge drinking increased serum sodium and oxidative stress markers, but NAC did not mitigate these effects.", "population_specificity": "Healthy students (20 male, 20 female), aged 23 \u00b1 2 years.", "effective_dosage": "Not specified", "study_duration": "Single intervention (before binge drinking session)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:56.068307+00:00"}
{"study_id": 27108, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the protective effects of N-acetylcysteine (NAC), N-acetylcysteine amide (NACA), and di-N-acetylcysteine amide (diNACA) against oxidative stress and other stressors in rat retinal cell cultures.", "results_summary": "NAC, NACA, and diNACA showed concentration-dependent cytoprotection against oxidative stress in retinal cell cultures, with NACA being the most effective against multiple stressors. NACA and NAC increased glutathione levels, while diNACA exhibited a different antioxidant mechanism and was uniquely effective against rotenone-induced toxicity.", "population_specificity": "Rat retinal cell cultures (macroglial-only, neuron-only retinal ganglion cell cultures, and mixed glia-neuron cultures).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:56.381954+00:00"}
{"study_id": 27113, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of N-Acetylcysteine on nerve regeneration in rats with sciatic nerve crush injury, focusing on histopathological, biochemical, and functional outcomes.", "results_summary": "NAC significantly improved histopathological markers (e.g., reduced inflammation, axonal degeneration) and functional recovery (higher sciatic functional index) in rats. It also positively influenced thiol-disulfide homeostasis, suggesting antioxidant effects.", "population_specificity": "Male Wistar rats with induced sciatic nerve crush injury.", "effective_dosage": "300 mg/kg intraperitoneal NAC once daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:56.624544+00:00"}
{"study_id": 27112, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 65, "quality_score": 90, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) improves tuberculosis treatment outcomes, including culture conversion and lung function recovery, in adults with moderate to far-advanced pulmonary tuberculosis.", "results_summary": "NAC increased glutathione levels and improved lung function recovery, particularly in participants with severe baseline lung impairment, but did not enhance stable culture conversion or MTB eradication. The effects on lung function appeared to persist beyond the NAC administration period.", "population_specificity": "Adults with moderate or far-advanced pulmonary tuberculosis, predominantly young, male, and HIV-negative.", "effective_dosage": "1200 mg oral NAC twice daily", "study_duration": "112 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:56.882472+00:00"}
{"study_id": 27115, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the protective effects of N-Acetylcysteine (NAC) against oxidative stress in heat-stressed skeletal muscle cells and its role in promoting muscle development.", "results_summary": "NAC reduced oxidative stress and heat shock response, increased cell viability, decreased apoptosis, and promoted muscle cell proliferation and differentiation by upregulating key muscle development markers.", "population_specificity": "Heat-stressed skeletal muscle cells (in vitro study).", "effective_dosage": "2 mM", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:57.842593+00:00"}
{"study_id": 27114, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to assess the impact of N-Acetylcysteine (NAC) on the cryopreservation of periodontal ligament tissues and teeth, and investigate its underlying mechanisms.", "results_summary": "NAC improved the survival rate and osteogenic differentiation ability of periodontal ligament cells, upregulated antioxidant enzymes (SOD-2 and Catalase), and inhibited cell apoptosis. It also activated the PI3K-AKT pathway, enhancing post-cryopreservation cell viability.", "population_specificity": "Periodontal ligament cells from freshly-extracted healthy human permanent teeth and rat teeth.", "effective_dosage": "Not specified", "study_duration": "Three months of cryopreservation", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:50:58.130980+00:00"}
{"study_id": 75467, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as a novel intervention for schizophrenia by targeting oxidative stress and ferroptosis pathways.", "results_summary": "The abstract suggests N-Acetylcysteine may address oxidative stress in schizophrenia, potentially improving clinical outcomes, but specific efficacy data are not detailed.", "population_specificity": "Individuals with schizophrenia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:02.223875+00:00"}
{"study_id": 75463, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to assess the use of N-Acetylcysteine (NAC) in treating bronchiolitis in PICU-admitted children and its association with PICU length of stay.", "results_summary": "NAC was used in 3.3% of cases, with mechanical ventilation strongly associated with its use (aOR 3.29). No medication, including NAC, was associated with decreased PICU LOS.", "population_specificity": "PICU-admitted children aged 24 months or younger with bronchiolitis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:03.226529+00:00"}
{"study_id": 75469, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specifically address N-Acetylcysteine; it focuses on cardiac complications in SLE and their management.", "results_summary": "The abstract does not report any findings related to N-Acetylcysteine.", "population_specificity": "Patients with systemic lupus erythematosus (SLE) experiencing cardiac complications.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:03.293063+00:00"}
{"study_id": 75468, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of fenoldopam with N-Acetylcysteine (NAC) for the prevention of acute kidney injury (AKI).", "results_summary": "The study found that it remains unclear whether fenoldopam is more or less effective than NAC in reducing the risk for AKI or the need for kidney replacement therapy (KRT).", "population_specificity": "Adults and children at risk of AKI following surgery, radiocontrast exposure, or sepsis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:04.885852+00:00"}
{"study_id": 75470, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the suitability of N-Acetylcysteine as a first-line therapy for trichotillomania (TTM) based on its safety and efficacy profile.", "results_summary": "N-Acetylcysteine was considered a suitable first-line therapy for TTM due to its favorable safety and efficacy profile, low risk of adverse effects, and significant benefits. Other drugs had limited evidence of variable efficacy.", "population_specificity": "Individuals with trichotillomania (TTM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:05.194881+00:00"}
{"study_id": 75475, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical value and immunomodulatory effects of N-Acetylcysteine (NAC) in treating bipolar disorder and schizophrenia.", "results_summary": "The study suggests NAC may be beneficial for treating bipolar disorder and schizophrenia, but further translational research is needed to confirm these findings. No specific efficacy data or adverse effects were detailed in the abstract.", "population_specificity": "Patients with schizophrenia and bipolar disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:06.275163+00:00"}
{"study_id": 75474, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) is effective in reducing aminoglycoside-induced ototoxicity in humans.", "results_summary": "Pooled analysis of two studies showed NAC significantly reduced ototoxicity (RR 0.112, 95% CI, 0.032-0.395; p = 0.0007). NAC was among the most effective antioxidants studied, though long-term benefits remain unclear.", "population_specificity": "Humans undergoing aminoglycoside treatment (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Up to 8 weeks in most studies; one study followed subjects for 1 year.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:06.851913+00:00"}
{"study_id": 75484, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine in improving survival in patients with alcohol-associated hepatitis.", "results_summary": "The study found that N-Acetylcysteine improved survival in large trials, indicating its potential benefit for patients with alcohol-associated hepatitis. The abstract does not provide detailed statistical outcomes but suggests a positive effect.", "population_specificity": "Patients with alcohol-associated hepatitis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:10.783313+00:00"}
{"study_id": 75479, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the potential anti-aging effects of cysteine supplementation, including N-acetylcysteine, on lifespan in mice, nematodes, and fruit flies.", "results_summary": "Cysteine supplementation significantly reduced mortality risk in mice and C. elegans but showed no significant effect in Drosophila except in transgenic flies. High doses had adverse effects in worms, and nondisease mouse models showed no benefit.", "population_specificity": "Mice, C. elegans (nematodes), and Drosophila (fruit flies), including transgenic flies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:11.422158+00:00"}
{"study_id": 75483, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether prophylactic N-Acetylcysteine (NAC) could prevent postoperative liver dysfunction in patients undergoing double-valve replacement (DVR) by leveraging its free radical scavenging properties.", "results_summary": "NAC significantly reduced postoperative liver dysfunction markers (LFT parameters) and improved outcomes like ventilation duration and ICU stay, though other outcomes (e.g., AF, mortality) showed non-significant improvements.", "population_specificity": "60 patients undergoing double-valve replacement (mitral and aortic valve replacement).", "effective_dosage": "Not specified (prophylactic intravenous NAC).", "study_duration": "Intervention administered perioperatively (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:12.227266+00:00"}
{"study_id": 75491, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the otoprotective potential of N-Acetylcysteine in preventing cisplatin-induced hearing loss, particularly in children.", "results_summary": "N-Acetylcysteine was identified as one of eight substances with potential otoprotective effects against cisplatin-induced ototoxicity, acting through antioxidant mechanisms to reduce hearing loss. The study suggests it may improve quality of life, especially in pediatric patients.", "population_specificity": "Pediatric population undergoing cisplatin treatment for cancer.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:13.775790+00:00"}
{"study_id": 75490, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the perioperative benefits of N-Acetylcysteine (NAC), including its potential for analgesia, reduction in opioid use, and other positive effects such as arrhythmia prevention and improved organ function.", "results_summary": "NAC may improve perioperative analgesia and reduce postoperative opioid use, with additional benefits like arrhythmia prevention, decreased contrast-induced nephropathy, improved liver function post-transplant, and better pulmonary outcomes. However, larger randomized trials are needed to confirm these effects.", "population_specificity": "Patients undergoing surgery, including cardiac surgery, liver transplant, and general anesthesia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:13.951121+00:00"}
{"study_id": 75492, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine the effectiveness of N-Acetylcysteine in improving outcomes following hepatectomy, particularly its impact on biochemical markers and clinical outcomes.", "results_summary": "The study found no significant improvements in key biochemical parameters or clinical outcomes (length of stay, transfusion rates, morbidity) with NAC administration, suggesting limited effectiveness in reducing hepatic dysfunction post-hepatectomy.", "population_specificity": "388 patients undergoing hepatectomy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:13.968956+00:00"}
{"study_id": 75493, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to summarize the role of oxidative stress in IBD and evaluate the potential of antioxidant therapies, including N-Acetylcysteine, in managing and treating IBD.", "results_summary": "The study found that oxidative stress markers are elevated in IBD patients and correlate with disease severity, suggesting that antioxidants like N-Acetylcysteine could be beneficial in treatment. However, specific efficacy data for N-Acetylcysteine alone were not detailed.", "population_specificity": "Patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:15.034369+00:00"}
{"study_id": 75473, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine (NAC) could improve symptoms and functional connectivity in patients with chronic post-concussion syndrome (PCS).", "results_summary": "NAC treatment significantly improved cognitive, emotional, and sensory symptoms in PCS patients, along with notable changes in resting-state functional connectivity, particularly in key brain networks like the default mode, salience, and executive control networks. These improvements correlated with symptom relief.", "population_specificity": "Fifty patients with chronic PCS persisting for at least 3 months post-injury.", "effective_dosage": "Combination of daily oral and weekly intravenous infusions (specific amounts not detailed).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:16.787784+00:00"}
{"study_id": 75494, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine (as part of GlyNAC) could improve physical function in older individuals by enhancing mitochondrial health.", "results_summary": "The study found that GlyNAC (a combination of glycine and N-Acetylcysteine) improved physical function in older individuals by increasing mitochondrial biogenesis and energetics, reducing oxidative damage, and improving mitochondrial quality control.", "population_specificity": "Older individuals experiencing age-related declines in skeletal muscle mass and function.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:18.410757+00:00"}
{"study_id": 75495, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention N-Acetylcysteine or its study.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its effects.", "population_specificity": "Hereditary cystatin C amyloid angiopathy (HCCAA) patients with L68Q mutation.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:18.459714+00:00"}
{"study_id": 75496, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the potential mechanisms through which N-Acetylcysteine (NAC) offers protection against polycystic ovary syndrome (PCOS).", "results_summary": "The study found that NAC may counteract oxidative stress, exhibit anti-inflammatory and anti-apoptotic properties, and influence insulin signaling pathways, suggesting potential benefits for managing PCOS. Most studies reviewed indicated positive effects, though further research is needed.", "population_specificity": "Individuals with polycystic ovary syndrome (PCOS).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:20.043434+00:00"}
{"study_id": 75497, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the potential of hydroxyl PAMAM dendrimer-N-acetylcysteine (OP-101) as a targeted treatment for hyperinflammation in severe COVID-19 patients.", "results_summary": "The study found that OP-101 showed promise in preclinical models for targeting activated microglia and astrocytes at brain injury sites, with positive Phase 2a results for treating severe COVID-19-related hyperinflammation.", "population_specificity": "Hospitalized adults with severe COVID-19.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:21.718526+00:00"}
{"study_id": 75498, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine in improving survival and outcomes for patients with acute liver failure.", "results_summary": "The study suggests that N-Acetylcysteine, alongside supportive measures and intensive therapy, contributes to improved survival in acute liver failure patients. It is highlighted as part of medical treatment, though liver transplantation remains necessary for nonresponders.", "population_specificity": "Patients with acute liver failure, particularly those with no prior liver disease, experiencing hepatic encephalopathy and coagulopathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:22.392072+00:00"}
{"study_id": 75499, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 87, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as an augmentation strategy for improving total symptomatology in schizophrenia and schizoaffective disorder.", "results_summary": "N-Acetylcysteine demonstrated a significant reduction in total symptomatology (SMD = -0.87, 95% CI = -1.27; -0.47), outperforming placebo and showing efficacy comparable to other nutraceuticals like citicoline and L-lysine.", "population_specificity": "Patients with schizophrenia or schizoaffective disorder.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:22.953694+00:00"}
{"study_id": 75500, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to determine whether high-dose NAC significantly reduces the risk of hepatotoxicity in patients with massive paracetamol overdoses.", "results_summary": "The study found mixed results, with one observational study showing no significant difference in hepatotoxicity, while two others reported significant reductions. The lack of standardized inclusion criteria made comparisons difficult, and no solid evidence supports high-dose NAC's efficacy in massive overdoses.", "population_specificity": "Patients with massive paracetamol overdoses (definitions varied by study).", "effective_dosage": "Standard dose (300 mg/kg over 20-21 hours); high-dose specifics not detailed.", "study_duration": "20-21 hours (standard regimen).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:24.013427+00:00"}
{"study_id": 75501, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 60, "study_goal": "The researchers aimed to evaluate whether N-Acetylcysteine is an effective treatment for RYR1-related myopathy (RYR1-RM).", "results_summary": "The study found that N-Acetylcysteine was explored as a potential therapy for RYR1-RM, but no conclusive evidence of its effectiveness was reported. Recent clinical trials focused on other drugs like Rycal ARM210 showed more promising results.", "population_specificity": "Patients with RYR1-related myopathy (RYR1-RM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:25.578549+00:00"}
{"study_id": 75502, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the immunological mechanisms underlying steatotic liver diseases (SLD) and evaluate the potential of N-Acetylcysteine as an immunomodulatory therapeutic agent.", "results_summary": "The abstract suggests N-Acetylcysteine is among the immunological modulations targeting hepatocyte death and inflammatory reactions in SLD, but specific efficacy data or outcomes are not detailed.", "population_specificity": "Patients with metabolic dysfunction-associated alcoholic liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:26.555867+00:00"}
{"study_id": 75504, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to systematically review the molecular mechanisms by which NAC affects RSV infection and air pollution, and to identify knowledge gaps in this field.", "results_summary": "The study identified 28 studies conducted in human cellular models, but the abstract does not provide specific findings on NAC's effects. The focus was on reviewing existing literature rather than presenting new experimental results.", "population_specificity": "Human cellular models (specific population not detailed).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:27.799272+00:00"}
{"study_id": 75503, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the safety and pharmacokinetics of a combined antioxidant therapy (CAT) including N-Acetylcysteine in healthy subjects as a potential treatment for myocardial reperfusion injury.", "results_summary": "The study found that CAT significantly increased plasma drug concentrations and antioxidant biomarkers compared to placebo, with no serious adverse events reported, suggesting safety and potential efficacy for reperfusion therapy.", "population_specificity": "Healthy subjects (n = 18)", "effective_dosage": "Two different doses/infusion rates tested in a single 90-minute intravenous infusion (specific amounts not detailed in abstract)", "study_duration": "Single 90-minute infusion with follow-up for 30 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:28.027506+00:00"}
{"study_id": 75505, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to review evidence for pharmacological approaches, including N-Acetylcysteine, in treating pediatric treatment-resistant OCD.", "results_summary": "N-Acetylcysteine was listed among several pharmacological approaches with varying levels of investigation and support, largely based on adult data, but the abstract does not specify its efficacy or results for pediatric OCD.", "population_specificity": "Youth with treatment-resistant obsessive-compulsive disorder (OCD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:29.760477+00:00"}
{"study_id": 75506, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential protective effects of N-Acetylcysteine against cardiovascular and pulmonary outcomes attributed to air pollution exposure.", "results_summary": "N-Acetylcysteine showed potential beneficial effects, but the limited number of existing trials indicates a need for further research to confirm its efficacy.", "population_specificity": "Individuals exposed to air pollution (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:29.968182+00:00"}
{"study_id": 75507, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to assess the effectiveness and safety of N-acetylcysteine (NAC) supplementation in improving health outcomes, such as reducing crisis frequency, pain severity, and adverse effects, in people with sickle cell disease (SCD).", "results_summary": "The study found that NAC (1200 mg) may not be better than placebo at reducing crisis frequency, pain severity, or improving quality of life, adverse effects, hospitalization frequency, or hemoglobin levels, with low to very low certainty of evidence.", "population_specificity": "People with sickle cell disease (SCD).", "effective_dosage": "1200 mg NAC.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:31.858824+00:00"}
{"study_id": 75510, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the potential of N-acetylcysteine, as a dietary supplement, to mitigate pesticide-induced oxidative harm by enhancing glutathione synthesis.", "results_summary": "The study suggests that N-acetylcysteine, along with glycine, can bolster glutathione synthesis, potentially mitigating oxidative stress caused by pesticide exposure. However, more large-scale experimentation is needed to validate its efficacy and long-term effects.", "population_specificity": "Non-target organisms exposed to pesticides (specific human or animal population not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:34.622849+00:00"}
{"study_id": 75508, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to explore whether N-Acetylcysteine (NAC) could serve as an adjunctive medication to improve therapeutic effects in Parkinson's disease (PD) treatment.", "results_summary": "The abstract suggests NAC may be used as an adjunctive medication to enhance therapeutic effects in PD, but specific efficacy data or outcomes related to NAC are not detailed.", "population_specificity": "Parkinson's disease patients (general, no specific subgroup mentioned).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:35.188230+00:00"}
{"study_id": 75512, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the potential of repurposing N-acetylcysteine for the treatment of alcohol dependence.", "results_summary": "The abstract mentions N-acetylcysteine as a candidate for further investigation in treating alcohol use disorder, but no specific efficacy results are provided.", "population_specificity": "Not specified (general alcohol use disorder population implied).", "effective_dosage": "Not provided.", "study_duration": "Not provided.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:36.744664+00:00"}
{"study_id": 75511, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to investigate the efficacy of N-Acetylcysteine (NAC) in reducing exacerbations and improving symptoms and quality of life in patients with COPD or chronic bronchitis (CB/pre-COPD).", "results_summary": "NAC significantly reduced exacerbation incidence in both COPD and CB/pre-COPD patients and improved symptoms and quality of life, particularly in CB/pre-COPD patients. Sensitivity analyses confirmed these findings.", "population_specificity": "Patients with COPD or chronic bronchitis (CB/pre-COPD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Studies with durations longer than 5 months were included in sensitivity analyses.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:36.791472+00:00"}
{"study_id": 75509, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the role of N-acetylcysteine as an etiology-specific treatment for paracetamol-induced acute liver failure (ALF) and its impact on patient outcomes.", "results_summary": "The study found that N-acetylcysteine improves outcomes in paracetamol-induced ALF, particularly in hyper-acute presentations, compared to other etiologies without specific treatments. It highlights that etiology-specific treatments like N-acetylcysteine contribute to better survival rates in ALF patients.", "population_specificity": "Patients with acute liver failure, specifically those with paracetamol-induced ALF.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:37.835026+00:00"}
{"study_id": 75515, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 30, "study_goal": "The researchers aimed to review existing literature on the efficacy of N-Acetylcysteine and other drugs in treating compulsive sexual behavior disorder (CSBD) and problematic pornography use (PPU).", "results_summary": "The abstract mentions N-Acetylcysteine as one of the pharmacological approaches for CSBD/PPU but notes that empirical support is scant, with data primarily from case studies, limiting generalizability.", "population_specificity": "Individuals with compulsive sexual behavior disorder (CSBD) and problematic pornography use (PPU).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:38.464972+00:00"}
{"study_id": 75513, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to explore N-Acetylcysteine (NAC) as a potential treatment for progressive multiple sclerosis (PPMS and SPMS) due to its antioxidant properties.", "results_summary": "The abstract mentions NAC as one of the treatments being explored for its antioxidant effects, but no specific results regarding its efficacy or outcomes in PPMS/SPMS are provided.", "population_specificity": "Patients with primary and secondary progressive multiple sclerosis (PPMS and SPMS).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:38.602199+00:00"}
{"study_id": 75516, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review the role of glutathione (GSH) in cell-mediated immune responses in individuals with HIV and AIDS-defining illnesses.", "results_summary": "The abstract suggests that adequate GSH supplementation reduces inflammation and slows the decline of CD4+ T cell counts in HIV-positive individuals, but it does not provide specific results regarding N-Acetylcysteine.", "population_specificity": "HIV-positive individuals and those with AIDS-defining illnesses.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:39.650653+00:00"}
{"study_id": 75518, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to explore the potential of N-Acetylcysteine as a pharmacological treatment for gambling disorder, alongside other glutamatergic agents.", "results_summary": "The abstract does not provide specific findings on N-Acetylcysteine's efficacy for gambling disorder, but it notes that glutamatergic agents, including NAC, were considered among other medications with varied results across studies.", "population_specificity": "Individuals with gambling disorder (GD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:43.478164+00:00"}
{"study_id": 75517, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether microneedling with N-acetylcysteine (NAC) was more effective than microneedling alone in treating persistent vitiligo lesions.", "results_summary": "The study found that microneedling with or without NAC improved vitiligo lesions, but the addition of NAC did not result in statistically significant greater improvement compared to the control group. Both groups showed significant improvement in lesion severity and repigmentation.", "population_specificity": "Patients with persistent and limited vitiligo seeking treatment at Rasool Akram Medical Complex.", "effective_dosage": "5% NAC ampoules during six microneedling sessions, plus 4.7% NAC cream applied once daily.", "study_duration": "Six sessions (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:44.892691+00:00"}
{"study_id": 75522, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine reduces oxidative stress and protects against thiopurine-induced liver injury in inflammatory bowel disease patients.", "results_summary": "N-Acetylcysteine decreased myeloperoxidase concentrations but did not protect against thiopurine-induced increases in serum liver enzyme tests. Other biomarkers, including oxidative stress markers and liver enzyme activity, remained unchanged.", "population_specificity": "Inflammatory bowel disease patients with thiopurine-induced increased serum liver tests.", "effective_dosage": "1200 mg twice a day", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:45.936738+00:00"}
{"study_id": 75524, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention N-Acetylcysteine or its effects.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its outcomes.", "population_specificity": "The study focuses on clinical chorioamnionitis and its management, not N-Acetylcysteine.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:45.973795+00:00"}
{"study_id": 75523, "supplement_id": 1364, "safety_score": "40", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to compare the safety and efficacy of N-Acetylcysteine with other drugs and placebo in treating Idiopathic Pulmonary Fibrosis (IPF).", "results_summary": "The study found that N-Acetylcysteine had higher all-cause mortality compared to placebo, indicating poorer safety and efficacy for IPF treatment. SUCRA's scatterplot also showed N-Acetylcysteine was less effective than placebo in improving lung function.", "population_specificity": "Patients with Idiopathic Pulmonary Fibrosis (IPF) (total of 6,208 patients across 24 studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:48.346916+00:00"}
{"study_id": 75525, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine could prevent disease progression, reduce hospitalization rates, and lower mortality in early-stage COVID-19 patients.", "results_summary": "N-Acetylcysteine increased oxygen saturation by 1.33%, reduced hospitalization rates, shortened hospitalization duration, and resulted in zero mortality compared to the control group.", "population_specificity": "Symptomatic COVID-19 patients with oxygen saturation above 92%, excluding pregnant individuals and those vaccinated against COVID-19.", "effective_dosage": "Not specified", "study_duration": "Follow-ups on days 7 and 14, with hospitalized patients monitored for one month post-hospitalization.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:48.778930+00:00"}
{"study_id": 75526, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to investigate the safety and efficacy of N-acetylcysteine (NAC) as an adjunctive therapy to intravenous recombinant tissue plasminogen activator (rtPA) in acute ischemic stroke.", "results_summary": "The study found no significant differences in adverse events, intracranial hemorrhage, or mortality between the NAC+rtPA and rtPA-alone groups, but noted a slightly improved early neurological outcome in the NAC group. Functional outcomes and three-month mortality were similar between groups.", "population_specificity": "Patients presenting with acute ischemic stroke within 4.5 hours of onset.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Intervention duration not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:53.578665+00:00"}
{"study_id": 75529, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to assess whether N-Acetylcysteine, as a natural intervention, could prevent cognitive impairments in rodents treated with cancer therapy.", "results_summary": "N-Acetylcysteine was among the natural interventions that showed consistent positive outcomes in preventing cognitive impairment in rodents receiving cancer therapy, with 75% of natural interventions demonstrating effectiveness.", "population_specificity": "Rodents (animal model)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:54.077872+00:00"}
{"study_id": 75530, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the neurobiology of substance use disorders (SUDs) and discuss integrative pharmacology developments, including potential combination treatments, to improve clinical outcomes.", "results_summary": "The abstract does not provide specific results about N-Acetylcysteine but highlights the need for novel combination treatments targeting multiple neurobiological mechanisms involved in SUDs.", "population_specificity": "Patients with substance use disorders (SUDs).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:55.816398+00:00"}
{"study_id": 75528, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to investigate the feasibility of a larger clinical trial and assess the anti-inflammatory and clinical benefits of high-dose NAC (2400 mg/day) in bronchiectasis patients, focusing on sputum neutrophil elastase as a primary outcome.", "results_summary": "High-dose NAC showed anti-inflammatory benefits, improved aspects of quality of life and lung function measures, and was safe and well-tolerated. The study was stopped early due to the COVID pandemic, limiting complete data collection.", "population_specificity": "Patients with bronchiectasis (mean age 72 vs. 62 years, 44-50% male).", "effective_dosage": "2400 mg/day", "study_duration": "6 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:56.121450+00:00"}
{"study_id": 75531, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC), alongside standard treatment, could restore cellular homeostasis and reduce organ damage in patients with septic shock.", "results_summary": "The study found that NAC, along with vitamin C and melatonin, contributed to a decrease in the SOFA score, indicating reduced organ damage in septic shock patients. However, specific cytokine level changes were not statistically significant for NAC compared to melatonin.", "population_specificity": "131 patients with septic shock", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:57.323130+00:00"}
{"study_id": 75532, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention N-Acetylcysteine or its study goals.", "results_summary": "The abstract does not discuss N-Acetylcysteine or its effects.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:51:59.427495+00:00"}
{"study_id": 75527, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to compare the effectiveness and safety of a simplified two-bag N-Acetylcysteine (NAC) regimen versus the traditional three-bag regimen for treating acetaminophen poisoning.", "results_summary": "The study found no difference in liver injury outcomes between the two-bag and three-bag NAC regimens. However, the two-bag regimen was associated with fewer non-allergic anaphylactoid reactions, fewer treatments for adverse events, and fewer interruptions in therapy.", "population_specificity": "Patients with acetaminophen poisoning.", "effective_dosage": "Two-bag/20-hour regimen (combining the traditional first and second bags into a single four-hour infusion).", "study_duration": "Varied by study, but the two-bag regimen typically involved a 20-hour infusion.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:01.061820+00:00"}
{"study_id": 75533, "supplement_id": 1364, "safety_score": "65", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to assess the clinical effectiveness and safety of N-Acetylcysteine (NAC) combined with pirfenidone compared to pirfenidone monotherapy in treating idiopathic pulmonary fibrosis (IPF).", "results_summary": "The study found that NAC plus pirfenidone did not significantly reduce the incidence of skin effects, mortality, or other side effects compared to pirfenidone monotherapy. The combination also showed uncertain effects on pulmonary function parameters like FVC, DLco, and 6MWT.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF) from Japan, Europe, and China.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:02.972992+00:00"}
{"study_id": 75519, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the mechanisms of action and clinical prospects of N-acetylcysteine as an antidote for acetaminophen overdose.", "results_summary": "The study found that N-acetylcysteine, a glutathione precursor, is effective as an antidote for acetaminophen overdose by mitigating liver injury caused by reactive metabolites. It highlighted ongoing development of adjunct treatments to enhance its efficacy.", "population_specificity": "Not specified (general clinical context for acetaminophen overdose)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:03.786791+00:00"}
{"study_id": 75534, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine, when combined with colistin, could enhance colistin's activity against bacterial biofilms, particularly in multi-drug resistant bacteria.", "results_summary": "N-Acetylcysteine showed promising results in combination with colistin, suppressing biofilm formation and destroying established biofilms, while also reducing the required dosage of colistin and preventing resistance.", "population_specificity": "Multi-drug resistant bacterial infections (in vitro or clinical context not specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:04.055667+00:00"}
{"study_id": 75521, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the benefits and tolerability of N-Acetylcysteine as an adjunct therapy to risperidone for treating irritability in ASD.", "results_summary": "N-Acetylcysteine, when used adjunctively with risperidone, outperformed placebo in treating ASD-associated irritability, with effects mediated through multiple neurobiological systems. The medication was reported to be safe and tolerable.", "population_specificity": "Children with autism spectrum disorder (ASD) exhibiting irritability.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:04.621999+00:00"}
{"study_id": 75535, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of N-acetylcysteine (NAC) as adjuvant therapy for hospitalized COVID-19 patients.", "results_summary": "The study found that NAC led to a further decrease in C-reactive protein levels and may reduce mortality when combined with atazanavir/ritonavir and hydroxychloroquine. No deaths occurred in the atazanavir/ritonavir + HCQ + NAC group.", "population_specificity": "Hospitalized Iranian patients with COVID-19 (n=60).", "effective_dosage": "600 mg three times daily (TDS).", "study_duration": "Not specified in the abstract.", "interactions": "Combined with atazanavir/ritonavir + HCQ or Kaletra (lopinavir/ritonavir) + HCQ.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:05.971002+00:00"}
{"study_id": 75537, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to explore the role of mitochondrial dysfunction and oxidative stress in developmental programming of chronic diseases and the potential benefits of maternal antioxidant supplementation, including compounds like N-Acetylcysteine.", "results_summary": "The abstract does not provide specific findings on N-Acetylcysteine, focusing instead on general mechanisms of mitochondrial dysfunction and oxidative stress in developmental programming.", "population_specificity": "Offspring of mothers with gestational diabetes mellitus (GDM), maternal obesity (MO), or intra-uterine growth restriction (IUGR).", "effective_dosage": "Not provided", "study_duration": "Not provided", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:06.250346+00:00"}
{"study_id": 75538, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether IV N-acetylcysteine reduces mortality rates in acute aluminum phosphide poisoning compared to supportive treatment alone.", "results_summary": "The meta-analysis found a statistically significant reduction in mortality (43.95% vs. 66.27%) with IV N-acetylcysteine, though its effect on mechanical ventilation need was nonsignificant.", "population_specificity": "Patients with acute aluminum phosphide poisoning.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:07.500990+00:00"}
{"study_id": 75539, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine as a therapeutic agent for mitigating lens opacity in cataract development by acting as a glutathione precursor.", "results_summary": "N-Acetylcysteine showed promise in reducing lens opacity when applied topically, suggesting its potential as a therapeutic intervention for cataracts. The study also highlighted its role in addressing glutathione depletion, a key factor in cataract pathogenesis.", "population_specificity": "Not specified (general focus on cataract development, likely involving models or human lens studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:09.793259+00:00"}
{"study_id": 75542, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to examine the potential benefit of N-acetylcysteine supplementation for managing painful diabetic neuropathy (PDN).", "results_summary": "Preliminary research suggests that N-acetylcysteine supplementation is associated with promising results in improving PDN symptoms, though detailed efficacy data are not provided.", "population_specificity": "Patients with painful diabetic neuropathy (PDN).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:10.969736+00:00"}
{"study_id": 75540, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine (NAC) reduces postoperative pain and opioid use in patients after back surgery.", "results_summary": "Patients given NAC (150 mg/kg) required 16\u201322% fewer opioids in the first 2 days after surgery, took longer to request pain medication, and reported lower pain scores compared to placebo. Initial small sample sizes made definitive conclusions difficult, but the larger follow-up group supported these findings.", "population_specificity": "Patients undergoing back surgery.", "effective_dosage": "0, 50, 100, and 150 mg/kg (final phase used only 150 mg/kg).", "study_duration": "First 2 days after surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:12.482719+00:00"}
{"study_id": 75543, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if N-Acetylcysteine (NAC) as an adjunct to NSAIDs could reduce pain and improve pain-related disability in patients with acute radiculopathy secondary to lumbar disc herniation.", "results_summary": "NAC showed significantly greater reductions in pain (VAS) and disability (ODI) from week 4 to week 8 compared to placebo. More NAC-treated patients also reported \"very much\" or \"much improved\" on global improvement scales (CGIC and PGIC).", "population_specificity": "62 patients with acute lumbar radiculopathy associated with disc herniation.", "effective_dosage": "600 mg twice daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:13.756149+00:00"}
{"study_id": 75544, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to classify pediatric patients with cerebrovascular disorders by imaging phenotype to guide genetic testing and treatment, including the use of N-Acetylcysteine as a preventative measure.", "results_summary": "N-Acetylcysteine was listed among preventative treatments for pediatric cerebrovascular disorders, but the abstract does not provide specific efficacy data or outcomes related to its use.", "population_specificity": "Pediatric patients aged zero to 21 years with monogenic causes of cerebrovascular disorders.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:13.963849+00:00"}
{"study_id": 75541, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine the efficacy of N-Acetylcysteine in combination with clobetasol for treating Lichen planopilaris (LPP) compared to other medical interventions.", "results_summary": "The study found that the combination of clobetasol and N-Acetylcysteine significantly improved the Lichen planopilaris activity index (LPPAI) compared to clobetasol alone, suggesting it as an effective treatment approach. The triple-combination of clobetasol, hydroxychloroquine, and N-Acetylcysteine was proposed as the most effective strategy.", "population_specificity": "251 patients with Lichen planopilaris (LPP).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:14.323245+00:00"}
{"study_id": 75545, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers compared the efficacy and survival outcomes of IPF patients treated with antifibrotics (nintedanib or pirfenidone) versus an older cohort treated with immunosuppressive drugs and/or N-Acetylcysteine.", "results_summary": "The study found that the antifibrotic cohort (nintedanib/pirfenidone) had significantly better survival (58.2 months) compared to the older cohort treated with immunosuppressants/N-Acetylcysteine (39.9 months). N-Acetylcysteine was not directly evaluated for efficacy or safety in this study.", "population_specificity": "Patients with idiopathic pulmonary fibrosis (IPF).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:15.618197+00:00"}
{"study_id": 75547, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 30, "study_goal": "The researchers examined the use of N-Acetylcysteine as part of the treatment for DRESS-induced multi-organ dysfunction syndrome in an elderly patient on antitubercular therapy.", "results_summary": "N-Acetylcysteine was administered alongside pulse methylprednisolone and dialysis, but the patient's condition deteriorated, leading to death due to MODS. The study did not demonstrate efficacy in reversing organ failure or improving survival in this case.", "population_specificity": "A 74-year-old male with DRESS and MODS during antitubercular therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:16.191788+00:00"}
{"study_id": 75550, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify a study goal related to N-Acetylcysteine.", "results_summary": "The abstract does not report any findings related to N-Acetylcysteine.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:18.594223+00:00"}
{"study_id": 75548, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and acceptability of N-Acetylcysteine (NAC) as an augmentation strategy for antipsychotic medication in treating psychotic disorders.", "results_summary": "The study found no significant difference in PANSS scores (total, positive, negative, or general psychopathology) between NAC and placebo groups at both short-term (\u226424 weeks) and long-term (>24 weeks) intervals. Drop-out rates also showed no statistical difference between the groups.", "population_specificity": "Patients with psychotic disorders (total of 594 participants from eight randomized controlled trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Two time points assessed: \u226424 weeks and >24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:18.952412+00:00"}
{"study_id": 75549, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of N-Acetylcysteine in managing COPD, specifically for patients with high exacerbation risk, as part of a broader guideline update on pharmacologic therapy.", "results_summary": "The study recommends N-Acetylcysteine for specific COPD populations with high exacerbation risk, alongside other therapies like triple combination therapy, but does not provide detailed efficacy data. It positions N-Acetylcysteine as an option without strong comparative evidence.", "population_specificity": "Symptomatic COPD patients with spirometry-confirmed diagnosis, particularly those with moderate/severe dyspnea and high exacerbation risk.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:20.809755+00:00"}
{"study_id": 75553, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify interventions, including N-Acetylcysteine, that significantly reduce mortality in patients with hepatic failure.", "results_summary": "The study found that N-Acetylcysteine administration in acute liver failure was one of the few interventions with a documented survival benefit.", "population_specificity": "Adult critically ill or perioperative patients with acute liver failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:22.300741+00:00"}
{"study_id": 75552, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the potential of N-Acetylcysteine in addressing cocaine craving by examining glutamatergic alterations and network disturbances in the nucleus accumbens.", "results_summary": "The abstract does not provide specific results regarding N-Acetylcysteine's effects, focusing instead on the study design and the underlying mechanisms of cocaine craving.", "population_specificity": "Individuals with cocaine use disorder (specific details not provided).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:22.699992+00:00"}
{"study_id": 75554, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential of N-Acetylcysteine (NAC) combined with probenecid as a neurotherapeutic strategy for traumatic brain injury (TBI) by addressing BBB permeability and target engagement.", "results_summary": "The study suggests that co-administration of NAC with probenecid may overcome BBB limitations, presenting a promising strategy for TBI treatment, though further clinical investigation is needed to confirm efficacy.", "population_specificity": "Children with severe TBI", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "Probenecid (a membrane transporter inhibitor) was used to enhance NAC's effects.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.813442+00:00"}
{"study_id": 75551, "supplement_id": 1364, "safety_score": "75", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety, efficacy, and treatment protocols of N-acetylcysteine for paracetamol overdose, including its adverse effects and optimal administration methods.", "results_summary": "N-acetylcysteine was found to be highly effective for paracetamol overdose when administered early, either intravenously or orally, though IV administration could cause anaphylactoid reactions. Simplified and slower infusion regimens reduced adverse effects, and larger doses over longer periods were recommended for severe cases.", "population_specificity": "Patients with paracetamol overdose, particularly those with risk factors or severe poisoning.", "effective_dosage": "Not specified (larger doses over longer periods mentioned for severe cases).", "study_duration": "Not specified (longer periods mentioned for severe cases).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:24.888326+00:00"}
{"study_id": 75555, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to elucidate the mechanisms by which N-Acetylcysteine acts as an antidote for acetaminophen-induced liver injury, focusing on mitochondrial dysfunction and adaptive cellular responses.", "results_summary": "The study found that N-Acetylcysteine mitigates acetaminophen-induced liver injury by addressing mitochondrial superoxide and peroxynitrite formation, preventing mitochondrial permeability transition pore opening, and supporting adaptive mechanisms like autophagy and mitochondrial biogenesis. The mechanisms identified in mice were shown to translate to human hepatocytes and APAP overdose patients.", "population_specificity": "Mice and human hepatocytes, with implications for APAP overdose patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:25.956929+00:00"}
{"study_id": 75556, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential role of N-Acetylcysteine as an adjuvant therapy in reducing schizophrenia symptoms.", "results_summary": "The study found that N-Acetylcysteine significantly reduced overall schizophrenia symptoms when used as an adjuvant therapy. However, detailed efficacy metrics or statistical significance were not provided in the abstract.", "population_specificity": "Patients with schizophrenia (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:26.093345+00:00"}
{"study_id": 75557, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the hepatoprotective effect of N-Acetylcysteine (NAC) on anti-TB drug-induced liver injury (DILI) in Indian TB patients.", "results_summary": "NAC significantly improved liver function parameters (ALT, ALP, bilirubin) and showed persistent hepatoprotective effects at 4 and 8 weeks, though some oxidative stress biomarkers did not reach statistical significance. Adverse effects (itching, rashes) were similar between NAC and placebo groups.", "population_specificity": "Newly diagnosed TB patients in India with normal baseline liver function.", "effective_dosage": "600 mg tablet twice daily.", "study_duration": "4 weeks of intervention, followed by 4 weeks of follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:28.808826+00:00"}
{"study_id": 75558, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to investigate the efficacy of adjuvant N-Acetylcysteine (NAC) in individuals with treatment-resistant PTSD.", "results_summary": "The study found no significant differences between NAC and placebo in PTSD symptom reduction at 12 weeks, but significant long-term benefits in craving duration and resistance were observed at 64 weeks.", "population_specificity": "Adults with treatment-resistant PTSD unresponsive to first-line treatment.", "effective_dosage": "2.7 g/day orally", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:29.506597+00:00"}
{"study_id": 75559, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to assess the feasibility, safety, and efficacy of N-Acetylcysteine (NAC) in treating alcohol use disorder (AUD) through a randomized, placebo-controlled trial.", "results_summary": "NAC was found to be feasible and safe, with no significant differences in adverse events between groups. While there was a significant effect of NAC on some alcohol consumption measures (e.g., drinks per drinking day), the results were inconsistent across time, suggesting the need for larger, longer-term trials to confirm efficacy.", "population_specificity": "42 participants with AUD, 56% of whom had alcohol-related liver disease.", "effective_dosage": "2400 mg/day", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:31.969636+00:00"}
{"study_id": 75561, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the clinical and biochemical effects of administering N-Acetylcysteine (NAC) to critically ill COVID-19 patients in the ICU.", "results_summary": "The abstract does not provide specific results, but the study sought to determine if NAC could counteract free radicals and improve clinical outcomes in ICU patients with COVID-19.", "population_specificity": "Critically ill COVID-19 patients admitted to the ICU.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:32.556812+00:00"}
{"study_id": 75562, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to determine whether N-Acetylcysteine amide (NACA) could alleviate symptoms in a patient with Mitchell syndrome (MITCH).", "results_summary": "After administering NACA, some symptoms were relieved, and the patient's condition improved, though the abstract does not specify which symptoms or the extent of improvement.", "population_specificity": "A 7-year-old Chinese girl with MITCH caused by a heterozygous ACOX1 gene mutation.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:32.739268+00:00"}
{"study_id": 75560, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effect of a supplement containing N-Acetylcysteine (MetioNac\u00ae) on lipid and biochemical parameters in metabolic syndrome patients at risk of MAFLD.", "results_summary": "The study found that MetioNac\u00ae supplementation significantly reduced TG, VLDL-c, total cholesterol, LDL-c, and glucose levels while increasing HDL-c. Weight loss was observed, but reductions in AST and ALT were not statistically significant.", "population_specificity": "Patients with metabolic syndrome and at risk of MAFLD (FIB-4 < 1.30) who were indicated for weight reduction (n = 15).", "effective_dosage": "Three capsules of MetioNac\u00ae per day (exact N-Acetylcysteine dosage not specified).", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:33.076874+00:00"}
{"study_id": 75564, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of oral N-Acetylcysteine (NAC) on oxidative stress, depression, and anxiety symptoms in patients with multiple sclerosis (MS).", "results_summary": "NAC supplementation significantly reduced serum malondialdehyde (MDA) levels and improved anxiety symptoms (HADS-A scores) in MS patients, but did not significantly affect serum nitric oxide (NO), erythrocyte glutathione (GSH), or depression symptoms (HADS-D scores).", "population_specificity": "42 patients with multiple sclerosis (MS), divided into intervention (n=21) and control (n=21) groups.", "effective_dosage": "600 mg twice daily", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:35.712886+00:00"}
{"study_id": 75563, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether adding N-Acetylcysteine (NAC) to prednisolone treatment improves hearing recovery outcomes in patients with idiopathic sudden sensorineural hearing loss (ISSHL).", "results_summary": "The study found that combining NAC with prednisolone resulted in better hearing recovery compared to prednisolone alone, with multivariable analysis showing NAC treatment as a significant positive factor. Negative prognostic factors included age, diseased opposite ear, pantonal ISSHL, and lack of NAC treatment.", "population_specificity": "793 patients (median age 60 years; 50.9% women) diagnosed with ISSHL at a tertiary university otorhinolaryngology department.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:36.398140+00:00"}
{"study_id": 75566, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of N-Acetylcysteine as an augmentation agent for OCD symptoms in patients with partial response to SRI monotherapy.", "results_summary": "The study included 5 RCTs on N-Acetylcysteine, but it was not among the most supported augmentation agents (lamotrigine, memantine, and aripiprazole were highlighted). The abstract does not specify the magnitude or consistency of N-Acetylcysteine's effects.", "population_specificity": "Adults with obsessive-compulsive disorder (OCD) who were partial responders to SRI monotherapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:39.395051+00:00"}
{"study_id": 75570, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine NAC's efficacy in reducing cigarette and cannabis craving and use among dual users of tobacco and cannabis.", "results_summary": "The abstract does not report specific results, as the study is ongoing, but it highlights NAC's potential efficacy based on prior animal studies and RCTs.", "population_specificity": "Adult cigarette-cannabis co-users (n=60).", "effective_dosage": "3600 mg per day.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:40.592381+00:00"}
{"study_id": 75568, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (NAC) in treating dengue fever-associated hepatitis, given its known benefits in other liver conditions.", "results_summary": "The majority of reviewed articles reported positive outcomes when NAC was used alongside supportive care, but data on NAC's sole efficacy from large randomized trials remain unclear.", "population_specificity": "Patients with dengue fever-associated hepatitis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:40.671813+00:00"}
{"study_id": 75569, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to summarize evidence from systematic reviews on the efficacy, effectiveness, and safety of interventions, including N-Acetylcysteine, for reducing pain and disability in adults with complex regional pain syndrome (CRPS).", "results_summary": "The study found no high-certainty evidence for the effectiveness of any therapy for CRPS, including N-Acetylcysteine, and noted that current systematic reviews are of low methodological quality.", "population_specificity": "Adults (\u226518 years) diagnosed with CRPS.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:41.462320+00:00"}
{"study_id": 75567, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 88, "quality_score": 90, "study_goal": "The researchers aimed to determine whether IV N-acetylcysteine (NAC) is superior to placebo and non-inferior to ambroxol in improving sputum viscosity and expectoration difficulty in patients with respiratory diseases and abnormal mucus secretion.", "results_summary": "NAC showed statistically significant superiority to placebo and non-inferiority to ambroxol in reducing sputum viscosity and expectoration difficulty. The safety profile of IV NAC was confirmed as well-tolerated, with no new safety concerns identified.", "population_specificity": "Hospitalized patients with respiratory diseases (e.g., acute/chronic bronchitis, emphysema, mucoviscidosis, bronchiectasis) and abnormal mucus secretion from 28 centers in China.", "effective_dosage": "600 mg IV infusion twice daily.", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:42.165609+00:00"}
{"study_id": 75571, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify high-risk factors and develop a predictive model (DIALF-5) for transplant-free survival in non-APAP drug-induced acute liver failure, including the role of N-acetylcysteine.", "results_summary": "N-acetylcysteine was associated with transplant-free survival and incorporated into the DIALF-5 model, which showed high predictive accuracy (AUROC 0.915 for 21-day TFS), outperforming MELD and KCC.", "population_specificity": "Patients with non-APAP drug-induced acute liver failure (n=482, with 147 in the external validation cohort).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:44.776666+00:00"}
{"study_id": 75572, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to review available evidence on the use of N-acetylcysteine (NAC) as an adjunctive treatment to enhance antibiotic efficacy in multidrug-resistant infections.", "results_summary": "NAC demonstrated potential as an adjunctive treatment by inhibiting biofilm formation, disrupting preformed biofilms, and reducing bacterial viability in various infections, including cystic fibrosis, COPD, and severe systemic infections. Clinical and preclinical evidence supports its use, but further research is needed to optimize treatment schedules.", "population_specificity": "Patients with multidrug-resistant infections, including cystic fibrosis, bronchiectasis, COPD, and severe systemic infections (e.g., KPC-producing Klebsiella pneumoniae, CR-Acinetobacter baumannii).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:46.138895+00:00"}
{"study_id": 75573, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential of N-acetylcysteine as a therapeutic agent for inflammatory bowel disease (IBD) by inhibiting ferroptosis.", "results_summary": "The abstract suggests that N-acetylcysteine, along with other agents, may help mitigate ferroptosis-related features like glutathione depletion and lipid peroxidation, potentially relieving IBD symptoms. However, specific efficacy data for N-acetylcysteine alone are not detailed.", "population_specificity": "Patients with inflammatory bowel disease (IBD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:47.648112+00:00"}
{"study_id": 75575, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine as an intervention for acute liver failure within the context of the ALFSG registry and substudies.", "results_summary": "The abstract does not provide specific findings regarding N-Acetylcysteine's effects, only mentioning it as one of two interventional substudies conducted.", "population_specificity": "Adult patients with acute liver failure (ALF) or acute liver injury (ALI) enrolled in the ALFSG registry.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:48.462129+00:00"}
{"study_id": 75576, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the effect of N-Acetylcysteine (NAC) as an adjuvant therapy on oxidative stress markers and organ dysfunction in septic shock patients.", "results_summary": "NAC, along with other antioxidants, reduced multiple organ failure (MOF) and oxidative stress markers while increasing total antioxidant capacity (TAC) and thiol levels. The study did not isolate NAC-specific results but grouped it with other antioxidants showing overall positive effects.", "population_specificity": "131 septic shock patients with multiple organ failure and low vitamin C levels.", "effective_dosage": "Not specified", "study_duration": "5 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:49.207846+00:00"}
{"study_id": 75578, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to determine the optimal dose, safety, and efficacy of N-Acetylcysteine (NAC) in preventing cisplatin-induced hearing loss (CIHL) in pediatric and adolescent patients.", "results_summary": "NAC significantly reduced the likelihood of CIHL and the need for hearing interventions, with a recommended phase II dose of 450 mg/kg. NAC also increased glutathione (GSH) levels, and genetic factors (GSTP1) influenced its otoprotective effects.", "population_specificity": "Children and adolescents newly diagnosed with nonmetastatic, cisplatin-treated tumors.", "effective_dosage": "450 mg/kg intravenously, administered 4 hours post-cisplatin.", "study_duration": "Duration of cisplatin therapy (specific length not stated in abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:52.099535+00:00"}
{"study_id": 75579, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether multivariable/machine learning models could predict treatment response (including N-Acetylcysteine) in adults with cannabis use disorder.", "results_summary": "Machine learning models showed moderate accuracy (AUCs 0.72-0.77) in classifying treatment responders, with N-Acetylcysteine's specific efficacy not directly highlighted beyond its inclusion in the combined intervention.", "population_specificity": "Adults with cannabis use disorder (n=302) in a U.S. outpatient clinical trial.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:52.631267+00:00"}
{"study_id": 75577, "supplement_id": 1364, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of high-dose N-Acetylcysteine (NAC) in combination with standard therapy for treating acquired thrombotic thrombocytopenic purpura (TTP).", "results_summary": "Twelve patients with acquired TTP treated with high-dose NAC, plasma exchange, and steroids showed a quick clinical response (median 5.5 days), with all patients surviving after a median follow-up of 29 months. The treatment was feasible and well tolerated, suggesting NAC's potential benefit and safety when added to standard care.", "population_specificity": "Twelve consecutive patients diagnosed with acquired thrombotic thrombocytopenic purpura (TTP).", "effective_dosage": "150 mg/kg/day", "study_duration": "Median follow-up of 29 months (intervention duration not explicitly stated).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:53.169597+00:00"}
{"study_id": 75580, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to analyze the efficacy and safety of N-Acetylcysteine (NAC) in preventing post-contrast acute kidney injury (PC-AKI) in patients with pre-existing kidney impairment undergoing non-interventional radiological examinations requiring IV contrast media.", "results_summary": "The study found that NAC was not associated with a significant reduction in PC-AKI or all-cause mortality, with very low to low certainty of evidence. Secondary outcomes like renal replacement therapy requirement, serious adverse events, and hospital stay length also showed no significant improvement with NAC.", "population_specificity": "Patients with pre-existing kidney impairment undergoing non-interventional radiological examinations requiring IV contrast media.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:55.287255+00:00"}
{"study_id": 75581, "supplement_id": 1364, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (NAC) in reducing ischemia-reperfusion injury and improving outcomes in liver transplantation.", "results_summary": "NAC significantly reduced primary graft nonfunction, postoperative complications, and liver enzyme levels while improving 2-year graft survival, though it increased intraoperative cryoprecipitate and red blood cell requirements. Subgroup analysis indicated NAC administration to recipients was more effective than other modes.", "population_specificity": "Liver transplant recipients and donors (total 1121 participants, 550 receiving NAC).", "effective_dosage": "Not specified (various administration modes).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:56.242345+00:00"}
{"study_id": 75582, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to investigate potential medical therapies for obstructive sleep apnea syndrome (OSAS), including N-acetylcysteine (NAC), focusing on its molecular effects and diagnostic potential.", "results_summary": "The study identified NAC as one of the most promising pharmacological therapies for OSAS, though it noted that further experimentation is required to confirm its efficacy. NAC was highlighted for its potential to address oxidative stress and related systemic dysfunctions in OSAS patients.", "population_specificity": "Patients with obstructive sleep apnea syndrome (OSAS).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:56.740625+00:00"}
{"study_id": 75565, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy of an antioxidant combination (including N-Acetylcysteine) in improving metabolic, endocrine, and clinical parameters in women with PCOS, comparing it to oral contraception and a combination of both.", "results_summary": "The antioxidant combination reduced insulin resistance (HOMA-IR) and improved clinical parameters like hirsutism, acne, irregular menstruation, and quality of life, with no statistical differences between treatment groups.", "population_specificity": "Non-diabetic women with polycystic ovary syndrome (PCOS).", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:52:57.143026+00:00"}
{"study_id": 75583, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the efficacy of febuxostat combined with traditional treatment (including N-Acetylcysteine) in preventing contrast-induced acute kidney injury (CI-AKI) in CKD Stage 3 patients undergoing PCI.", "results_summary": "The study found that the incidence of AKI was significantly lower in the group receiving febuxostat alongside traditional treatment (including N-Acetylcysteine) compared to the control group receiving only traditional treatment. Independent risk factors for AKI included avoidance of febuxostat, among other variables.", "population_specificity": "120 CKD Stage 3 patients with acute coronary syndrome referred for PCI and stenting.", "effective_dosage": "Not specified for N-Acetylcysteine (only febuxostat dosage provided).", "study_duration": "Not specified for N-Acetylcysteine (intervention timing was pre- and post-PCI for febuxostat).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:00.492277+00:00"}
{"study_id": 75584, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To evaluate the efficacy of intravenous N-acetylcysteine (NAC) in preventing contrast medium-associated acute kidney injury (CA-AKI) after endovascular treatment (EVT) of peripheral arterial disease (PAD).", "results_summary": "Intravenous NAC significantly reduced CA-AKI development (13% in NAC+ vs. 33.3% in NAC- group). Serum thiol-disulphide levels were effective biomarkers for detecting CA-AKI risk and monitoring NAC efficacy.", "population_specificity": "85 adult patients undergoing EVT for PAD.", "effective_dosage": "600 mg NAC intravenously before the procedure.", "study_duration": "Single preprocedural administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:00.618123+00:00"}
{"study_id": 75586, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of N-Acetylcysteine (NAC) as an add-on treatment for improving core and associated symptoms of autism spectrum disorder (ASD).", "results_summary": "The study found that NAC, when used as an add-on treatment, was associated with significant improvement in symptoms such as irritability, hyperactivity, and lethargy compared to placebo. The mechanisms may involve suppression of proinflammatory activation and immune cell imbalances.", "population_specificity": "Individuals with autism spectrum disorder (ASD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:01.331245+00:00"}
{"study_id": 75587, "supplement_id": 1364, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to explore the role of N-Acetylcysteine in preventing oxidative stress-induced intestinal injuries, particularly in the context of hyperoxia in newborns.", "results_summary": "The study suggests that N-Acetylcysteine, along with other antioxidant molecules, plays a protective role against hyperoxia-induced intestinal damage by mitigating oxidative stress and inflammation, potentially reducing the risk of necrotizing enterocolitis (NEC).", "population_specificity": "Newborns exposed to hyperoxia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:03.734096+00:00"}
{"study_id": 75585, "supplement_id": 1364, "safety_score": "80", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine the efficacy of long-term oral N-Acetylcysteine (NAC) therapy in reducing acute exacerbations and improving lung function in chronic obstructive pulmonary disease (COPD) patients.", "results_summary": "The meta-analysis found no significant differences between NAC and placebo groups in acute exacerbations, lung function (FEV1, FVC), quality of life (St George's Respiratory Questionnaire), glutathione levels, or adverse events. NAC did not reduce exacerbation risk or improve lung volume decline in COPD patients.", "population_specificity": "Chronic obstructive pulmonary disease (COPD) patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:05.222541+00:00"}
{"study_id": 28891, "supplement_id": 1392, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the safety and efficacy of oleoylethanolamide (OEA) with rimonabant as an antiobesity treatment, focusing on behavioral effects and satiety stimulation.", "results_summary": "OEA reduced food intake similarly to rimonabant but without the adverse effects like increased grooming or decreased motor activity. OEA primarily decreased eating activity and temporarily increased resting time, suggesting a safer satiety-stimulating profile.", "population_specificity": "Mice", "effective_dosage": "5 or 10 mg/kg, intraperitoneal", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:13.405397+00:00"}
{"study_id": 28895, "supplement_id": 1392, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Oleoylethanolamide (OEA) induces satiety by activating oxytocinergic neurotransmission in hypothalamic neurons.", "results_summary": "The study found that OEA stimulates oxytocin neurosecretion from the paraventricular nucleus (PVN) and enhances oxytocin expression in hypothalamic neurons, supporting its role in promoting satiety. These effects peaked 2 hours after OEA administration.", "population_specificity": "Not specified (likely animal models based on methodology).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:13.537301+00:00"}
{"study_id": 28888, "supplement_id": 1392, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of chronic OEA treatment on ischemia-induced spatial cognitive impairments, electrophysiology behavior, and hippocampal neurogenesis in rats.", "results_summary": "Daily OEA treatment significantly improved spatial cognitive deficits, attenuated LTP inhibition, enhanced hippocampal neurogenesis, and increased BDNF and PPAR\u03b1 expressions in MCAO rats.", "population_specificity": "Middle cerebral artery occlusion (MCAO) rat model.", "effective_dosage": "30 mg/kg daily.", "study_duration": "Chronic (exact duration not specified in abstract).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:13.621707+00:00"}
{"study_id": 28894, "supplement_id": 1392, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether oleoylethanolamide (OEA) could reduce L-DOPA-induced dyskinesias in a Parkinson's disease model without compromising L-DOPA's therapeutic effects.", "results_summary": "OEA reduced dyskinetic symptoms and molecular markers of dyskinesia without affecting motor activity or L-DOPA's benefits. Its antidyskinetic effects were mediated by TRPV1 receptors, and no tolerance to OEA was observed.", "population_specificity": "Hemiparkinsonian mice with 6-OHDA striatal lesions.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:13.806004+00:00"}
{"study_id": 28893, "supplement_id": 1392, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether combining PPAR\u03b1 activation (via OEA) with \u03b23-adrenergic stimulation (via CL316243) enhances energy balance, thermogenesis, and metabolic improvements in adipose tissue.", "results_summary": "Co-administration of OEA and CL316243 reduced food intake and body weight, increased energy expenditure, improved lipid metabolism, and promoted brown-like features in white adipose tissue, suggesting therapeutic potential for obesity.", "population_specificity": "Animal model (specific species not mentioned in abstract)", "effective_dosage": "OEA (5 mg/kg), CL316243 (1 mg/kg)", "study_duration": "6 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:14.056967+00:00"}
{"study_id": 28889, "supplement_id": 1392, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether changes in seminal plasma concentrations of oleoylethanolamide (OEA) affect sperm quality and its role in male fertility.", "results_summary": "OEA concentrations were lower in men with sperm abnormalities, and in vitro exposure to OEA significantly improved sperm motility and viability without affecting mitochondrial activity. The study suggests maintaining normal OEA levels in seminal plasma is crucial for sperm function.", "population_specificity": "Ninety men attending an infertility clinic for semen analysis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Exocannabinoids (e.g., THC, CBD) may compete with OEA, potentially disrupting its function.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:53:14.223021+00:00"}
